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Diet is a key factor in the development and progression of Inflammatory Bowel Disease
(IBD). A variety of diets have been studied with IBD patients. This cross-sectional survey
identified current healthcare practitioner views on different diets and their efficacy with IBD
patients. Diets were rated on awareness, compliance, and contributors to success by participants
(n = 181). Frequencies were conducted, and ANOVA with Duncan pairwise comparison or chisquare analysis were used to determine significant differences. Most participants (96%) and
98% of registered dietitians (RD) considered using diet to help treat IBD patients. RDs perceived
the low fiber or low residue diet easiest for patient compliance (4.2 ± 1.0, P < .05), and the
specific carbohydrate diet hardest for patient compliance (2.4 ± 1.4). Initial and follow up
consultations with a RD significantly contributed to patient success across all diets, and greater
involvement from the RD may solve issues with compliance.
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CHAPTER I
INTRODUCTION
Inflammatory bowel disease (IBD) is a set of conditions characterized by chronic
inflammation of the gastrointestinal (GI) tract.1 Inflammation is defined as “how the body reacts
to infection, irritation, or injury, characterized by redness, swelling, warmth, and pain.
Inflammation is a type of ‘non-specific immune response”.2 Bowel is defined as “the part of the
alimentary canal below the stomach, the intestine”.3 Disease is defined as “a disorder of structure
or function in a human, especially one that produces specific symptoms or that affects a specific
location and is not simply a result of a physical injury”.4 Two types of IBD diagnoses currently
exist, which are Crohn’s disease (CD) and ulcerative colitis (UC).1 In CD, inflammation presents
in patches throughout the entire GI tract, although the terminal ileum is typically affected.1 In
UC, inflammation begins in the anus and extends throughout the large intestine in a continuous,
uninterrupted pattern.1 IBD patients suffer from symptoms that include persistent diarrhea,
abdominal pain, rectal bleeding/bloody stools, weight loss, and fatigue.1
Both CD and UC are thought to be caused by a patient’s abnormal response to his/her
own immune system.5,6 While the exact cause of this abnormal response is not yet known, it is
postulated that a patient’s genetics, diet, and environment all play a role in the progression of the
disease.5,6
There are correlations between dietary habits and the initial development of IBD. Many
studies show a rise in both the incidence and prevalence of IBD in southern Europe, Asia, and
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developing countries where a western lifestyle and dietary habits are becoming increasingly
popular.7 This is particularly seen in first generation immigrant children who show similar IBD
prevalence and incidence patterns to the indigenous people.7
In humans, gut bacteria are critical to a host of physiological processes including the
digestion of nutrients, the development of the immune system, and resistance against pathogens.8
An alteration in the gut microbiota is associated with IBD.8 The factors that influence the
progression of IBD also influence the gut microbiota and recent studies suggest a critical
connection between gut microbiota and chronic intestinal inflammation.8
It is clear that diet is an important factor in shaping the microbiome. Foodborne microbes
transiently colonize the gut, suggesting that food may not only select for commensal bacterial
species, but serve as a reservoir for new bacterial introductions.9 Intentional introduction of
prebiotic food ingredients and foods high in fiber can also change the abundance of bacterial
species in the gut. Despite the inherent stability of the gut microbiome over time, diet
composition continues to subtly alter its composition, driving the development of the microbiota
through adulthood.9
Diet is a key factor in the development and progression of IBD.7 It plays a critical part in
gut homeostasis, microbial composition and functioning, the gut barrier, host immunity, and the
gut physiology by regulating gut hormone release.7 The western diet varies greatly from
traditional diet of generations prior, with the biggest difference being a switch from a plant-based
to animal-based dietary pattern.7 Western diets typically provide more calories, more sugar, more
animal protein, and more ultra-processed foods.7 Diet may play a key role in the initiation and
exacerbation of IBD and its associated symptoms and may be a way to optimize the efficacy of
conventional treatment.7
2

Recently, a variety of diets have been studied to determine whether they may have a
positive effect on the symptoms suffered by patients with IBD. These diets include the Specific
Carbohydrate Diet (SCD), a low fermentable oligo, di, and monosaccharides and polyols
(FODMAPs) diet, a low fiber or low residue diet, Immunoglobulin G (IgG) targeted exclusion
diet, and a general exclusion diet. All of these modalities have shown promising results with
managing IBD symptoms. However, the diets have not undergone rigorous, double-blind,
randomized control trials. Unfortunately, the chronic nature of IBD and the length of time
required to fully study these diets makes conducting those types of studies difficult. In turn, the
researchers were interested in which dietary modalities practitioners are actually using in their
practices. With all of these dietary options becoming increasingly popular, it is important to
understand practitioners’ points of view. There are few currently published articles on
practitioners’ viewpoints on these diets, and a better understanding of their viewpoints may help
to drive future research regarding diet and IBD.
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CHAPTER II
LITERATURE REVIEW
After a search of the literature, 20s articles were selected and reviewed as the basis for
this study. The focus of these articles is the different types of diets being researched in various
settings throughout the world. The terms “Crohn’s disease”, “ulcerative colitis”, “inflammatory
bowel disease”, “diet”, “views”, “viewpoints”, “perceptions”, and “nutrition” were searched in
the PUBMED, EBSCO, Google Scholar, and the Mississippi State University Library databases.
The Relationship Between Diet and IBD
Diet contributes to gastrointestinal health via a direct effect on gut motility and barrier
function or an indirect effect on microbes.10 The gut microbiome is shaped by genetic and
environmental factors, and is comprised of a limited number of phyla that are dominated by
bacteroidetes and firmicutes.10,11 The immune system and gut barrier function are affected by
both microbe to microbe and host to microbe interactions, and diet impacts both of these
interactions.10,12 Global increasing incidence of IBD is associated with a western lifestyle.10,13,14
While there is a clear association between diet and IBD, a cause and effect has not been
established10,15,16 due to research limitations that may greatly affect findings such as inherent
variability and variations in methodology.10,17,18
Patients with IBD have a reduced diversity in their microbiome that leads to less
flexibility and adaptability.10 This may lead to a negative impact on functional changes. Frequent
phylum level observations are observed in patients with IBD.14,19 Increased Bacteroidetes and
4

firmicutes and decreased proteobacteria may allow for colonization by Enterobacteriaceae such
as E. Coli.10,20
These observed changes are mediated by access to nutrients and oxygen carriers.10,21 The
functional capacity of the microbiome is based on which bacteria are present, and functional
microbiota dysbiosis is common in IBD patients.10,22 When comparing IBD patients to controls,
decreased levels of the SCFA butyrate and acetate and increased amino acid levels were
observed in the IBD patients.10,23-25 An evaluation of the ability to modify microbiota and effect
on disease via dietary intervention is needed.10
In rodent models, many dietary components were associated with CD, including
increased fat, increased animal or milk fat, increased fat or sugar, gluten, maltodextrin,
emulsifiers, titanium dioxide, luminal iron, and aluminum.10,15,26-36 Increased animal protein
leads to an increased risk for UC.14,37-39 The main issue is that the western diet is not limited to
natural components.10 All of the above mentioned components are common in economically
developed countries where a western diet is prominent.10
Malnutrition
Malnutrition, an extraintestinal manifestation of IBD, is caused by suboptimal intake or
an alteration in caloric requirements and metabolism.10 Malabsorption, gastrointestinal losses,
and medications all contribute to malnutrition.40 An increased ratio of basal metabolic rate to fat
free mass is seen in IBD patients versus healthy controls.14,41-43 Malabsorption is commonly seen
in underweight patients in remission, and impaired gastric acid and pancreatic enzyme secretion
is observed in undernourished patients.44,45
The assessment of a patient’s nutrition status and the prevention and correction of deficits
is essential to the multidisciplinary management of IBD.10 Involuntary weight loss and being
5

underweight accompanies disease relapse.10 However, the normalization of body mass index
(BMI) at 2 years follow up was not significantly associated with increased fat free mass in CD46,
meaning that BMI may not be a good evaluation of body composition changes in IBD patients.10
Practitioners must be cautious when evaluating plasma micronutrient measurements in
the presence of systemic inflammatory response (high C-reactive protein).10 Iron, zinc, selenium,
copper, vitamin A, vitamin C, and vitamin E are affected by nutrient carrier protein
concentration changes and unlikely reflect total body stores.10,47-49 Registered dietitians are
essential to the care of IBD patients because of their ability to asses anthropometric information
and oral intake.10,50 The diagnosis of malnutrition may help predict IBD outcomes.10
Diet Practices and Beliefs of Patients with IBD
A prospective study based on a questionnaire was published in the IBD Journal that
targeted practices/beliefs of patients with IBD.51 Multiple variations in food habits and eating
patterns coupled with patient compliance in clinical therapy have led to a lack of robust IBD diet
recommendations.51 Four hundred IBD patients with a confirmed IBD diagnosis responded to a
questionnaire composed of two sections, one on demographics and disease characteristics, and
one on diet beliefs and food related behavior.51 Two hundred five UC patients and 156 CD
patients fully completed the survey.51 Forty-eight percent of the patients believed diet initiates
disease, and 57% believed diet triggers relapse.51 Fifty-six percent of patients modified their diet
after their initial IBD diagnosis.51 Only 28% believed that diet was more important than
medications regarding their treatment.51 Sixty-eight percent of patients imposed food restrictions
to prevent relapse.51 Forty-five percent avoided spicy foods, 32% avoided fatty foods, 24%
avoided fruits and vegetables, 22% avoided alcohol, 16% avoided soda, and 15% avoided milk.51
Sixteen percent of patients believed that certain foods improved symptoms during relapse, such
6

as high fiber foods (5%), low fiber foods (2%) and starch rich foods (1%).51 Patients also
believed that certain foods worsen symptoms, such as spicy foods (45%), fatty foods (29%),
alcohol (20%), fruits/vegetables (19%), and milk products (16%).51 Seventy-five percent of
patients shared the same menu as their family, 78% of patients did not refuse outdoor eating, and
66% of patients deprived themselves of their favorite foods to prevent relapse.51 Furthermore,
50% of patients received no nutrition advice from their healthcare providers, and 67% of patients
wanted more advice.51 Patients shared the sources of their IBD diet information.51 Thirty-one
percent received information from RDs, 17% from gastroenterologists, 12% from IBD nurses,
10% from primary care physicians, 8% from the internet, 5% from the UK Crohn’s and Colitis
website, and 2% from other IBD patients.51 Patients preferred sources for future information on
IBD was 45% from RDs, 36% from nurses, 29% gastroenterologists, 17% informational leaflets,
and 15% from primary care physicians.51 Seventy-five percent of IBD patients reported a change
in appetite and pleasure eating.51 Appetite was rated on a scale from 1-10, with a higher score
reflecting an improved appetite.51 Appetite was rated as 4.3 during relapses and 8 outside
relapses.51 Significantly more CD patients (87%, P < .0001) than UC patients (66%) believed
IBD affected their appetite.51 When separated by disease type, CD patients had a lower mean
appetite outside relapse (7.8 vs 8.3, P = .0009) and during relapse (3.2 vs 5, P <.0001) when
compared to UC patients.51 A significantly greater percent of CD patients (67%) compared to
UC patients (53%) believed diet triggered relapse.51 Lastly, a significantly greater percentage of
CD patients (77%) avoided certain foods to prevent relapse compared to UC patients (63%).51
Enteral Nutrition
Enteral nutrition (EN) and partial enteral nutrition (PEN) are sometimes used clinically to
induce and maintain remission in IBD patients.10 PEN is defined as less than 100% of calories
7

come from EN.10 EN typically induces clinical remission in 80% of patients regardless of
formula composition.10 Current guidelines on EN use with IBD patients from the European
Society for Parenteral and Enteral Nutrition are published.52
Gut rest is not the primary mechanism for remission53,54, but it is more likely that antiinflammatory effects, restoration of the epithelial barrier, and beneficial changes in the
composition of gut mircobiota.10,55 Usually exclusive EN works in 6 – 8 weeks, however if there
is no clinical response in 3 weeks, it is medically advised to use an alternative treatment.10 The
efficacy of EN is related to the exclusion of specific dietary components.10,56 This is indirectly
supported by studies.10,57 PEN with a normal diet does not lead to remission, but PEN with an
exclusion diet leads to remission in 70% of children and 69% of adults.10,56 Exclusive EN either
via a feeding tube or by drinking the formula is monotonous and leads to limited compliance and
success.10,58 Multiple PEN studies utilizing anywhere from 35 to 90% using several different
study designs have produced varying results.10
In one laboratory trial, 37 children with CD showed mucosal healing to be more
significant in patients consuming enteral nutrition versus corticosteroids.52,59 EN is often used as
the first line of defense in pediatric cases of IBD.52 Undernutrition greatly impacts growth in
children.60 Utilizing EN may delay or help the patient to completely avoid using
corticosteroids.52,61 EN is preferred to parenteral nutrition (PN), because PN has not been shown
to offer any advantage to patients with CD, and should only be used after surgery to improve
nutritional status when other modes of nutrition are not available.52,62 Overall, not enough
research exists to support the use of EN in acute exacerbations of IBD in adults, however, it’s
use should continue to be studied to determine if adults may receive the same benefits as
pediatric patients.52
8

Half Elemental, Half Free Diet
Researchers at Tokohu University Graduate School of Medicine in Japan conducted a
RCT with 51 patients to determine whether the maintenance of remission in patients with CD
can be achieved through a half elemental, half-free diet.63 In this study, half of the experimental
group’s calories came from home enteral elemental nutrition, consumed either orally or via a
nocturnal feeding tube, and the other half came from the patients consuming their usual,
unrestricted meals.63 The control group consumed their usual, unrestricted diet without any
modifications.63 The relapse rate was measured over a 2 year period to determine the outcome of
the study.63 A relapse was considered any patient who had a Crohn’s Disease Activity Index
(CDAI) of greater than 200 at any point during the follow up time frame.63 At an average follow
up of 11.9 months, patients in the experimental group saw a relapse rate of 34% vs a rate of 64%
in the control diet.63 At the fourth analysis, the trial was stopped because the relapse rate of the
half-elemental diet was significantly lower than those in the free diet group.63 The trial was one
of the first to demonstrate the effectiveness of a half-elemental diet as maintenance therapy for
Crohn’s disease.63 The researchers associated the effectiveness of the half-elemental diet with the
possible low content of lipids in the patients’ diets, which led to the reduction of proinflammatory eicosanoid synthesis.63
Elimination Diets
Elimination diets have not been researched adequately to analyze the induction of
remission, maintenance of remission, and improved functional symptoms in patients with IBD.10
Elimination diets include the general exclusion diet10, low fiber or low residue diet64,65, lactosefree diet64,66, gluten-free diet64, SCD67, Crohn’s Disease Exclusion Diet (CDED)56, IBD Anti-
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Inflammatory Diet (IBD-AID)68, IgG exclusion diet69, semi-vegetarian diet70, low FODMAPS
diet71, and others64,72-75.
Carbohydrate Focused Diets
Some of the diets patients use in their management of IBD that target the types
carbohydrates consumed include the Specific Carbohydrate Diet (SCD), low FODMAPs Diet,
and a gluten free diet.64 All carbohydrate restricted diets put patients at risk for insufficient
caloric intake and weight loss.64 Possible nutrient deficiencies can occur in carbohydrate
restricted diets such as folate, B12, B6, calcium, vitamin D, vitamin C, vitamin A, and
potassium.64
Unrefined Carbohydrate Fiber Rich Diet Versus Exclusion Diet
In a study published in 1985, 20 patients were randomly assigned to either an unrefined
carbohydrate fiber rich diet or an exclusion diet.76 In the exclusion diet, various foods were
tested during a ‘food testing stage’ to determine whether suspected specific foods caused
negative symptoms.76 The erythrocyte sedimentation rate (ESR), a laboratory marker of
inflammation, was measured before the diet was started and after 6 months had passed.76 Patients
on the unrefined carbohydrate fiber rich diet had all relapsed by the 6 months point. Patients on
the exclusion diet all saw a drop in ESR after 6 months.76 The study reported that no medical
treatment is totally effective for IBD, and that intense cooperation between the patient,
gastroenterologist, and registered dietitian (RD) is necessary in order for patients to succeed with
this dietary modality.76
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Low Fiber or Low Residue Diet
Low residue diets (<10 – 15 grams insoluble fiber/day) are typically recommended for
patients with severe inflammation or bowel strictures, although one small study showed no
significant differences in symptoms when compared to an unrestricted diet.64,65 In a low residue
diet, nuts, seeds, whole grains, corn hull, raw fruits with peels, and vegetables, especially
cruciferous, are avoided.64 This diet is not recommended long term because fiber is necessary for
the production of short chain fatty acids and is important in the support of colonocyte
function.64,65 Avoiding fiber long term can also lead to vitamin A, vitamin C, potassium, and
folate deficiencies.64
Lactose Free Diet
A lactose-free diet was mentioned because CD is associated with an increased rate of
malabsorption of lactose.64,66 Lactose is a disaccharide sugar commonly found in milk and milkbased products. Not all dairy products contain high amounts of lactose, such as cottage cheese,
butter, and aged cheese. Yogurt is thought to be tolerated due to the presence of active cultures.64
Avoiding lactose long term may lead to a vitamin D or calcium deficiency and both should be
adequately supplemented by those IBD patients who avoid lactose.64,77
Gluten Free Diet
The gluten free diet eliminates the protein gluten, found mostly in wheat, rye, and
barley.64 IBD patients have a 3-8 fold increased risk of celiac disease.64,78,79 Gluten may cause
direct activation of the innate immune system and decrease intestinal barrier function.64,80-84
However, no evidence supports that the gluten free diet has any effect on disease activity in
IBD.64
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Low FODMAPs Diet
The low FODMAPS diet bases food choices on the chemical structures and absorptive
capacities of certain carbohydrates in the small bowel.10,64,85 The idea is that humans lack the
enzymes to breakdown most oligosaccharides.64,86 When fructose and glucose are present in even
amounts, there is equal absorption in the proximal small bowel.64,78,86 However, if fructose
presence is greater than glucose, there tends to be fructose malabsorption that leads to functional
bowel symptoms.64,78,86
A high percentage of patients with IBD experience functional gastrointestinal symptoms
(FGS) during remission, and are less likely to respond to anti-inflammatory medical therapy.71,87
FODMAPS pass undigested through the small intestine to the colon, where they cause an
osmotic effect that brings water into the lumen.87 This causes intestinal wall distension, bloating,
pain, flatulence, constipation, and diarrhea.10,87 FODMAPs may also be fermented by gut
bacteria, causing FGS.87 Reducing FODMAPs consumption is thought to prevent this
fermentation, thus improving GI symptoms.87 Usually this diet is prescribed to people with
irritable bowel syndrome, however some studies have shown symptom improvement in those
with IBD.71,87,88 Unfortunately, evidence is lacking that shows a decrease in inflammation in
patients with IBD.87,89 Long term studies are needed to determine the effect that a low
FODMAPS diet has on inflammation, metabolism, and the microbiome.87
The Journal of Crohns and Colitis published a study on whether a low FODMAPS diet
reduces symptoms in patients with IBD.71 Seventy-two patients took part in the study.71 Each
patient met with a dietitian to review the low FODMAPS diet protocol, and were offered
additional sessions if needed.71 Patients answered questionnaires regarding gastrointestinal
symptoms prior to beginning the diet and 3 months afterwards.71 Symptoms such as abdominal
12

pain, diarrhea, bloating, and flatulence all decreased.71 Constipation actually increased in some
UC patients, although the finding was deemed statistically insignificant.71 When patients were
asked about the ease of adhering to the diet, the median response was a 3 on a scale from
1(easy)-10(hard), indicating that patients found it relatively easy to follow the protocol.71
Low FODMAPS Diet Perception Among Gastroenterologists
A recent cross-sectional survey study was published by The Journal of
Neurogastroenterology and Motility in 2018 assessing the perceptions of dietary therapies for
Irritable Bowel Syndrome (IBS) patients among 1500 United States Gastroenterologists.90 IBS is
a chronic functional GI disorder with symptoms such as abdominal pain, bloating, and changes
in stool quantity and quality.90 IBS is prevalent at a rate of 10-20% worldwide.90 Certain foods
are attributed to GI symptoms in IBS patients such as carbohydrates, fruits, vegetables, dairy,
beans, and legumes.90 Several diets have been studied in IBS patients, including the low
FODMAPS diet.90 The study sought to determine whether provider recommendations on diet
differ from the pre-consultation behaviors of patients, whether any specific practice patterns
warrant additional education and review, and if demographics affect views and
recommendations.90 The survey was composed of 4 sections including questions on
demographics, interpretation of patients’ perceptions of food and GI symptoms and initial selfmanagement of IBS, gastroenterologists approach to diet and IBS including specific diets, and
resources and barriers to the provision of effective diet therapy with IBS patients.90
There were more male than female responses and the responses were geographically
diverse.90 The majority of providers practiced in an academic or private GI setting, and 36.7%
had greater than 20 years of practice since initial training.90 Greater than 50% of
gastroenterologists responded that patients associate their GI symptoms with food and that
13

patient’s self-manage their IBS symptoms prior to seeking advice from a professional.90 Seventy
percent of practitioners reported IBS patients have rarely or almost never tried a low FODMAPs
diet before their initial visit.90 Three quarters of gastroenterologists recommend diet to greater
than 50% of their patients, and 50% of gastroenterologists recommend diet to greater than 75%
of their patients.90 Additionally, half of providers identified diet as a primary management tool
for IBS.90 Greater than 90% of practitioners responded that diet was the same or better than other
forms of treatment.90 Seventy-five percent of gastroenterologists responded that scientific
evidence was important or very important in the decision of whether or not to recommend a
diet.90 Seventy-seven percent of gastroenterologists usually or almost always recommended a
low FODMAPs diet, and 85% of gastroenterologists found the low FODMAPs diet effective or
somewhat effective.90 Greater than 50% of practitioners were comfortable providing diet
counseling.90 Only 21% of gastroenterologists usually or almost always refer IBS patients to a
RD for counseling.90 Only 31% of practitioners referred patients to a RD with specialty training
in GI disease.90 However, 78% of gastroenterologists believed a RD with an IBS focus would
enhance diet therapy for patients.90 The two most significant barriers identified to providing
effective dietary interventions for IBS patients included the complexities of the diets and
insurance coverage for a RD.90 The researchers stated that long term efficacy and safety data is
lacking for a low FODMAPs diet and IBS patients, and that there are methodological limitations
of current low FODMAPs studies with IBS patients.90 However, this could be true of all diet
studies in this population.90
Specific Carbohydrate Diet
The SCD eliminates sugars such as lactose, sucrose, and refined starch and flour, grains
(corn, rice, wheat), and legumes.64,91 Only monosaccharides such as glucose, fructose, and
14

galactose are allowed.64,91 The prevailing thought is that more complex carbohydrates are poorly
absorbed leading to bacterial overgrowth and fermentation in the small bowel.64,91,92 Byproducts
from this bacterial dysbiosis lead to gut inflammation.64,91,92 The SCD has shown to increase
microbial diversity, compared with a low residue diet that decreases microbial diversity.10,93
Proponents of the SCD suggest that patients stay on the diet for at least one year, compared to
the low FODMAPs diet where the suggestion is strict adherence for 6-8 weeks, and then gradual
reintroduction of one high FODMAP food every 4 days.64
In 2015, a case series study was published on patients utilizing the SCD.94 The SCD is
not a low-carbohydrate diet, but rather “a diet high in monosaccharides, solid proteins, fats, and a
high ratio of amylose to amylopectin containing vegetables, fruits, and nuts”.94 The diet has the
ability to provide optimum nutrition for the patient while decreasing the amount of disaccharides
that reach the colon, preventing and reversing the dysfunctional microbiota that is present in IBD
patients.94 Fifty patients were recruited for this study.94 Patients who were currently following the
SCD were asked to complete a 3-day diet history, their medical history, and a validated disease
activity index.94 GI symptoms were assessed within one week of filling out the survey.94 Each
symptom was rated on a scale from 1 to 10, with 10 being the most painful.94 Patients following
the SCD who were in remission reported having a high quality of life according to the Short
Quality of Life in Inflammatory Bowel Disease Questionnaire, reporting a mean score of 60.9
(range was 35-70).94 According to the study, the mean time for food preparation per week was
10.8 hours.94 The study also stated that it took participants an average of 29.2 days to notice
some improvement from the SCD.94 All patients included in this study were in remission, which
may have skewed results.94 However, the strength of this study is strong due to the extensive,
confirmed medical review by an experienced gastroenterologist.94 The study determined that at
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least a subgroup of IBD patients see benefits from following the SCD, and that some patients
who follow the diet will be able to discontinue immunosuppressive agents.94
A retrospective chart review was published in the World Journal of Gastroenterology that
focused on pediatric CD patients who began to follow the SCD on their own accord.95 Eleven
patients, 8 males and 3 females, with a mean age of 11.0 ± 3.2 years at diagnosis, were found to
meet the inclusion criteria and underwent detailed medical reviews.95 Only 3 patients practiced a
strict SCD without medication or liberalization of diet.95 Hematocrit values improved
significantly for those following the strict version of the SCD, indicating a decrease in anemia
among the patients.95 The ESR, an inflammatory marker mentioned earlier, significantly
decreased in patients following the strict SCD.95 Weight and height percentiles increased with 10
of the 11 patients following the strict SCD, indicating that growth in the pediatric population is
still possible even though the diet is quite restrictive.95 The advantage of the SCD versus EN is
that it offers the patient an opportunity to eat conventional, palatable foods as their main source
of energy, as opposed to tube feedings, which may disrupt the social dynamic around meals.95
Finally, the study states, “provider awareness is paramount to maintain a therapeutic alliance
with the patient and offer appropriate clinical monitoring”.95 This highlights the important role
that providers play in helping to implement dietary modalities as treatments for IBD.95
A retrospective study conducted at the Seattle’s Children's Hospital sought to determine
whether the SCD is able to decrease inflammation by changing the fecal microbiome from a proinflammatory to non-inflammatory state.96 A medical chart review was conducted from 2012
until 2014.96 Pediatric patients diagnosed with either CD or UC initially had remission induced
through medication or diet.96 The patients pediatric Crohn’s disease activity index or pediatric
ulcerative colitis activity index was measured prior to beginning the SCD, and evaluated at week
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0, week 2, and 6 months.96 A comparative analysis showed clinical and laboratory improvements
in 12 of 26 patients, and an enrichment of microbial diversity was observed.96 Some patients
discontinued their medications.96 For others, the diet was difficult to maintain, and 9 patients
experienced weight loss.96
Protein Focused Diets
Semi-Vegetarian Diet
One study that sparked interest among those in the IBD community in Japan was the use
of a semi-vegetarian diet to prevent relapse.70 The semi-vegetarian diet used in the study
consisted mostly of fruits, vegetables, and whole grains while limiting animal proteins as much
as possible.70 The study was a prospective, 2-year clinical trial with 22 patients.70 In order to be a
part of the study, patients had to be in remission that was induced either medically or
surgically.70 Fifteen of the 16 patients who finished the 2-year trial did not relapse when
following the semi-vegetarian diet.70 The cumulative relapse rate at 2 years was significantly
lower in the semi-vegetarian group compared to the omnivorous group.70
Red and Processed Meat Restriction
An intake of a high protein diet or red meat leads to increased production of bacterial
metabolites such as ammonia, indoles, phenols, and sulfites that harm the gut.10,97 Alternatively,
bacterial fermentation of non-digestible carbohydrates lead to the production of SCFA that serve
as an energy source for host epithelial cells and act as a signaling molecule with antiinflammatory, antioxidant, and immuno-modulatory properties, which in turn improves mucosal
barrier function.10,98
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A study published in 2019 assessed whether a diet low in red and processed meats would
reduce the rate of CD flares and cause a more quiescent disease course.72 The researchers stated
that diet is an attractive target for both prevention and treatment of CD.72 They used the Food
and Crohn’s Exacerbation Study, a prospective randomized trial, as a basis for their cohort.72 The
short CDAI was used to measure flares/activity.72 The participants were split into two groups,
high meat consumption and low meat consumption.72 High meat consumption was defined as
greater than two servings of red or processed meat per week and low meat consumption was
defined as one or less servings per month of red or processed meat.72 Red meat was considered
meat from livestock, and processed meat was considered any red/white meat that used smoking,
salting, curing or the addition of preservatives in its production process.72 Each group spent 49
weeks on their respective diets.72 A diet history questionnaire was completed at baseline and at
week 20.72 Two-hundred-thirteen participants completed the study.72 There were no statistically
significant differences in median fecal calprotectin, an intestinal inflammatory laboratory
marker, between the two groups.72 The study determined that the consumption of red/processed
meat does not reduce the risk of CD relapse in patients with quiescent disease.72 In turn,
researchers questioned whether the complete elimination of red/processed meat would produce a
result that is statistically significant.72
Whole Food, Plant Based Diet
In an interesting case report published in 2017, a 25 year old male was diagnosed with
moderately severe and active CD confirmed by a colonoscopy and a Harvey Bradshaw Index
(HBI) score, an indicator of disease severity, of 17.73 In January of 2015 after the initial
diagnosis, he was prescribed infliximab, which decreased his HBI to 5, indicating moderate
disease but not clinical remission.73 In March 2017, as part of a religious celebration, he gave up
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animal protein for 40 days and his HBI score went to 0 indicating clinical remission.73 The
patient decided to switch to a whole food, plant based diet consuming less than one serving of
meat per week.73 The patient followed this diet for all of 2017 and a follow up colonoscopy
confirmed complete mucosal healing.73 He stopped his medications, and continued in clinical
remission.73 According to the case report, only 10% of CD patients achieve long term remission,
and 50% of patients require surgery within 10 years of the initial diagnosis of CD.73
Fat Focused Diets
Fat restricted diets are also considered for IBD patients.64 Short chain fatty acids (SCFA)
and medium chain fatty acids (MCFA) are absorbed directly across the villi in the small
intestine. However, long chain fatty acids (LCFA) need bile salts and micelle formation in order
to be absorbed. The Western diet/lifestyle has increased total fat intake, especially saturated fats
and omega-6 fatty acids.64,99-101 Omega-3 fatty acid intake is decreased in the typical western
diet.64,99-101 As the typical western diet has increased internationally, IBD incidence has increased
as well.64,99-101
The omega-6 polyunsaturated fatty acids (PUFAs) linoleic acid (LA) and arachidonic
acid (AA) are pro-inflammatory.74 The omega-3 PUFAs eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), the major components of fish oil, and alpha-linolenic acid (ALA),
regulate inflammation by inhibiting genes that start the process.74,102,103 Studies have shown that
increased LA consumption leads to an increased risk of UC.74,104,105 Studies have also shown that
an increased intake of DHA decreases the chance of developing of CD.74,106 Eicosanoids, key
lipid mediators generated by omega-6 and omega-3 PUFAs, play an important role in immune
regulation and inflammation, and are also greatly involved in the IBD inflammation
process.74,107,108Omega-6 related eicosanoids induce the release of pro-inflammatory cytokines
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leading to the production of the chronic inflammatory mediators Interleukin (IL) and Tumor
Necrosis Factor (TNF).74,107,108 Colonic mucosa in active UC is associated with increased intake
of omega-6 PUFAs.74,109 Alternatively, omega-3 PUFAs lead to eicosanoids with little or no
inflammatory properties and inhibit cytokine production.74,110 Omega-3 PUFAs do lead to antiinflammatory molecules called SPMs that reduce the magnitude and duration of
inflammation.74,,111 Omega-3 PUFAs also alter the gut microbiome by improving dysbiosis
through increasing the lactobacillus species and reducing the Bacteroidaceae family.74,112
Multiple animal studies show that prolonged increased fat intake promotes colitis and
ileitis and decreases barrier function.64,113,114 A high fat diet also shifts microbiome composition
and gene expression.64,115,116 A diet high in omega-3 fatty acids prevented barrier dysfunction in
colitis predisposed mice.64,117,118 The importance of a fat restricted diet may lay in the ratio of
omega-6 to omega-3 fatty acids. Using an omega-6 food exchange guide, patients with IBD who
remained in remission had a ratio of 1:1, while those patients who relapsed had a ratio of 20:1 of
omega-6 to omega-3 fatty acids.64,119
Paleo Diet
A Paleo dietary pattern focuses on meat, fish, and fruits and vegetables.64 The diet is
based on the premise that while the human diet has greatly evolved over time, our basic genetics
have not.64 After the agricultural revolution, increased intake of grains and refined sugar led to
chronic diseases of affluence.64,120,121 In the Paleo Diet, 50-65% of calories come from plant
sources, and 35-45% of calories are from fish or meat.64 The diet restricts carbohydrates such as
grains, refined sugars, dairy, and potatoes, refined oils, and processed foods.64 Total protein,
fiber, and omega-3 fatty acid consumption increases while calorie and total fat consumption
remains the same.64,121 In a Paleo Diet, the ratio of these PUFAs are 1:1, but in the Western diet
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the ratio is 20:1 in favor of the omega-6 PUFAs.74 Additionally, the ratio of LA:ALA has
increased from 6.4 to 10 from 1909-1999 in the Western diet as a percentage of energy
contribution.74 Recent data show that the Paleo Diet is beneficial for weight loss, cardiovascular
disease, and type 2 diabetes.64,122,123 However, no data suggest its use for IBD, only
recommendations based on anecdotal evidence.64 Further research is needed on how fat intake
affects IBD patients and if the restriction of certain fats can assist in IBD management.64
Crohn’s Disease Exclusion Diet
The CDED is based on decreasing dietary components that impair innate immunity in
rodent models, increase gut permeability, cause dysbiosis, or allow bacteria to translocate
throughout the intestinal epithelium.10 The diet is rich in fiber and natural sources of resistance
starches.10 The increased consumption of fiber leads to increased SCFA production in the colon,
which have been associated with numerous other health benefits.73 The CDED limits emulsifiers,
flavor enhancers, sources of omega-6 fatty acids, and dairy products.73 Children who used the
CDED coupled with 50% PEN achieved clinical remission in 70% of participants.10,56 Six of the
seven participants only using CDED achieved clinical remission.10,56 This diet needs to be
evaluated in prospective randomized control trials (RCT).10
Other Diets
Glutamine Enhanced Diet
An interesting area of research within the realm of IBD is potentially increasing one’s
intake of glutamine to induce remission.124 Glutamine is an amino acid that is postulated to
maintain the integrity of the intestinal mucosa and prevent gut permeability degradation, help
nitrogen balance, and reduce inflammation.124 In a randomized control trial (RCT), 18 children
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with CD received either a standard diet, or glutamine enriched diet.124 The standard diet
contained only 4% glutamine in the amino acid pool, while the enriched diet contained 42%
glutamine.124 The study produced no significant difference between the groups in terms of
remission rate.124 Other studies produced similar results. However, they should be considered
with caution due to their low participation numbers.124 Larger trials are needed to determine if
glutamine can help induce remission in patients with IBD.124
IgG Targeted Exclusion Diet
A retrospective study from China was published in 2019 on the IgG targeted exclusion
diet.69 When a person has an allergic reaction, such as to peanuts or shellfish, Immunoglobulin E
(IgE) antibodies are produced by the body. In turn, it is suspected that when a person has a food
intolerance, IgG antibodies are produced. The thought is that classic food intolerances caused by
food allergies are based on an IgE mediated response. However, immediate reactions to foods are
rare in the IBD population.69 A delayed response by IgG antibodies may account for the adverse
reactions present in IBD. However, IgG antibodies can also be found in healthy people.69 The
purpose of the study was to analyze IgG/IgE serum levels against food antigens in IBD patients
to determine clinical relevance in the IBD population.69 Patients were included using the
diagnostic criteria established by the European Crohn’s and Colitis Organization, and were
excluded if they had bowel surgery within the past 3 months.69 One hundred thirty seven IBD
patients, 40 with UC and 97 with CD, and 50 healthy controls had their serum IgG and IgE
assays analyzed for 14 unique food antigens.69 Many CD patients (90.7%) had a positive IgG
rate (P < .0001), compared with 57.5% of UC patients and 42% of healthy controls.69 When
compared to the unique antigens, CD patients developed IgG antibodies to 3.8 foods, compared
to 2.56 foods for UC patients, and 1.57 foods for healthy controls.69 The total serum IgG for CD
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patients was 138.6 U/mL, was 115.6 U/mL for UC patients, and 105.9 U/mL for healthy
controls.69 When analyzing the unique antigens, both IBD patients and healthy controls had
increased IgG antibodies to eggs.69 This highlights how the healthy controls also produced IgG
antibodies.69 For CD patients, there were higher levels of IgG antibodies to tomatoes, corn, rice,
soy, wheat, and cod when compared to healthy control serum levels.69 In UC patients, there were
higher levels of IgG antibodies to tomatoes, corn, and rice when compared to healthy control
serum levels.69 There were only significant increases in IgG serum levels in CD vs UC
patients/healthy controls.69 When comparing food antigens in CD patients, patients with 3 or
more food antigens producing IgG antibodies increased the CDAI score versus only 2 antigens.69
In UC patients, 2 or more food antigens producing IgG antibodies increased the Mayo score
versus only 1 antigen.69 However, no significant differences were found between
positive/negative IgG antibodies in terms of CDAI and Mayo scores.69 Interestingly, females
were twice as likely to develop food intolerances, although again the finding was not
significant.69 The authors concluded that more research with the IgG targeted exclusion diet is
warranted.69
Auto-Immune Protocol
One other approach to dietary modification for IBD is the Auto-Immune Protocol
(AIP).75 The AIP is an extension of the Paleo Diet that incorporates changes that were previously
studied in the IBD population.75 The protocol is split into three phases.75 The initial elimination
phase removes grains, legumes, night shades such as tomatoes and potatoes (not sweet potatoes),
dairy products, eggs, coffee, alcohol, nuts, seeds, refined/processed sugars, oils, and additives
from the patient’s diet.75 Additionally, foods, additives, and medications (NSAIDs) that trigger
inflammation, dysbiosis, or symptomatic food intolerance are avoided.75 The consumption of
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fresh, nutrient-dense foods, bone broth, and fermented foods are emphasized.75 The patients are
also told to focus on sleep hygiene, stress management, their support system, and physical
activity.75 The next phase, the maintenance phase, is varied in duration and lasts until there is a
measurable increase in symptoms/wellbeing.75 The maintenance phase can last between 30-90
days and sometimes longer.75 The last phase is the staged reintroduction of food groups.75 During
this phase, patients identify unique food groups that cause symptoms while liberalizing their
diet.75 Patients were chosen for a prospective, uncontrolled observational study based on
symptomatic CD (HBI >= 5) and UC (Mayo>=3) confirmed by colonoscopy or video capsule
endoscopy, or a fecal calprotectin of 50 or higher.75 Each patient had access to a certified health
coach and RD for 1:1 counseling and education. Additionally, each patient received 2 AIP
books.75 Clinical remission was defined as having a HBI less than 5 for CD patients and a partial
Mayo score less than 2 for UC patients.75 Nine CD patients and 6 UC patients were included in
this study.75 Eleven patients achieved clinical remission by week 6, 6 CD patients and 5 UC
patients.75 All 11 patients who achieved clinical remission maintained it through week 11.75
Significant decreases were seen in the short IBD questionnaire, HBI scores, and Mayo scores.75
There were no significant changes in weight, C-reactive protein, and fecal calprotectin among
the patients.75 The study showed preliminary efficacy for IBD patients using the AIP.75 The
authors noted that achieving clinical remission by week 6 rivals conventional medical drug
therapies, and proposed that the AIP can be used as an adjunct to medicine even in patients with
moderate to severe disease.75 Limitations of this study include the fact that the researchers did
not determine how non-dietary aspects of the AIP contributed to effectiveness.75 This small study
suggests that dietary modification has the potential to decrease inflammation based on fecal
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calprotectin and endoscopy.75 Large RCTs are needed to better determine the efficacy of the AIP
on IBD patients.75
Clinician and Patient Perspective on Diet and IBD
A cross-sectional study published in the Journal of Human Nutrition and Dietetics in
2017 explained there is a lack of clear, evidence based guidelines regarding diet and IBD due to
a lack of RCTs and the blinding of subjects not being possible.125 The aim of the study was to
determine the attitudes of IBD patients and clinicians regarding the role of diet in pathogenesis
and symptomology of IBD.125 An anonymous survey was sent to the Crohn’s and Colitis of
Australia mailing list, the Australian IBD Association, and the Dietetic Association of
Australia.125 The survey was open to participants for 4 months.125 Nine hundred twenty-eight
patients responded to the survey with a mean age of 39.5 years old.125 Sixty-four percent of
patients had CD and 36% had UC.125
The results showed that 76% of patients believed that diet affects IBD, 27.3% lost
weight, 46.1% gained weight, 20% used a multivitamin, 7.8% used probiotics, and 6% used a
B12 supplement.125 Twenty-six percent of patients reported receiving diet advice from an IBD
specialist compared to 98% of gastroenterologists who reported giving dietary advice.125 Ninetyone percent of patients referred to a RD by their primary care physician or gastroenterologist saw
an RD versus only 46% of total patients.125 Fifty-six percent of CD patients saw a RD compared
with 40.8% of UC patients (P < .001).125 There was no difference in the perception of their diet
as healthy or needing improvement between patients who did or did not see a RD.125 Patients
who saw a RD were more likely to consider that the diet affected IBD (81.4% versus 72.4%, P =
.002).125 Half of IBD patients in this cohort followed dietary advice from a clinician.125
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Supplement and vitamin use increased among patients who had seen a RD (76.2% versus
69.1%, P = .025).125 Thirty-eight percent of patients were familiar with a low FODMAPS diet,
but the percentage doubled in patients who had seen a RD.125 Half of patients felt symptoms
worsened after eating spicy, high fiber, and dairy foods and nuts.2125 Sixty-one percent of
patients felt clinicians didn’t place importance on the role of diet in IBD.125
Clinicians (n=136) also filled out a similar survey on diet and IBD. Forty-six
gastroenterologists, 12 surgeons, and 73 RDs completed the survey.125 Forty-nine percent of
clinicians reported spending less than 10% of their time treating IBD patients, 24% worked with
IBD patients between 25% to 50% of their time, and 39% worked with IBD patients
approximately 50% their time.125 Ninety-four percent of total clinicians and 99% of RDs stated
that diet was a factor in symptoms, and 73% of total clinicians and 52% of RDs state that diet
affected a patients intestinal microbiota.125 However, only 44% of gastroenterologists stated that
diet played a role in the pathogenesis of IBD, and only 17% of RDs reported this (P = .003).125
Sixty percent of clinicians stated they provided diet education on a low FODMAPs diet.125 Only
42% of clinicians thought that they had similar views to patients regarding diet and IBD.125
The only distinctions between CD and UC patients in this study were that an increased
rate of CD patients associated weight change as a result of IBD treatment compared with UC
patients, fewer UC patients saw an RD compared to CD patients, and more CD patients thought
specialists placed emphasis on the role of diet and IBD compared with UC patients.125 Overall,
the study found adherence to dietary advice was poor, and that this may reflect a lack of efficacy
or lack of evidence.125
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CHAPTER III
METHODS
Study design
This study was cross-sectional in nature and designed to answer the following questions:
1. Which dietary modalities do healthcare practitioners provide to patients with IBD, and
why do they provide them?
2. What drives patient success or failure with these dietary modalities?
Modality Selection
This study focused on which whole food based dietary modalities healthcare practitioners
use in the management of IBD symptoms. The dietary modalities were chosen based on the
current body of evidence on the many being investigated for IBD. The 5 dietary modalities this
study focused on were a low fiber or low residue diet, a general exclusion diet, the low
FODMAPs diet, an IgG targeted exclusion diet, and the Specific Carbohydrate Diet.
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Table 3.1

Comparison of Three Defined Exclusion Diets*

Food Group
Fruits

Low Fiber or Low
Residue Diet64

Low FODMAPs Diet126

Specific Carbohydrate
Diet91

No raw fruits with peel,
berries, dried fruit

No apple, pear, mango,
cherries, fig, watermelon,
blackberries, peach, plum,
dried fruit, canned fruit

All fresh, dried, and
frozen fruit allowed

Canned fruit and fresh
fruit without peel allowed
Non-Starchy Vegetables

Starchy Vegetables
Grains

No cruciferous allowed

Without peels allowed
White rice allowed

Other fruits allowed
No artichoke, asparagus,
cauliflower, garlic, leek,
onion, spring onion,
mushrooms, snow peas
Eggplant, green beans,
bok choy, bell pepper,
carrot, cucumber, lettuce,
tomato, zucchini allowed
Potatoes allowed
No wheat, barley, rye

No whole grains

Oats, quinoa, rice, corn
allowed

Nuts and Seeds

None allowed

All allowed except
pistachios and cashews

Milk
Cheese
Yogurt
Beans and Legumes

All allowed
All cheese allowed
All allowed
Not allowed

Only lactose free allowed
Aged cheese allowed
Only lactose free allowed
Only soy allowed

Red Meat
Poultry
Fish
Eggs
Pork
Processed Meats
Butter
Oils

Allowed
Allowed
Allowed
Allowed
Allowed
Allowed
Allowed
Allowed

Allowed
Allowed
Allowed
Allowed
Allowed
Not allowed
Allowed
Allowed

Sweeteners

Allowed

No honey or high fructose
corn syrup

No fruit canned with
sugar
Allowed

Not allowed
None allowed

No seeds
All nuts allowed
None allowed
Aged cheese allowed
Only home-made allowed
No soy allowed
Certain beans allowed if
prepared properly
Allowed
Allowed
Allowed
Allowed
Allowed
Not allowed
Allowed
All allowed except
soybean
No sugar, maple syrup, or
high fructose corn syrup

Sugar or maple syrup
Honey allowed
allowed
*General exclusion diet and IgG targeted exclusion diet not included because of specificity to individual
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Participants
Practitioners were recruited from multiple areas in the United States through email
correspondence with both individuals and groups. The largest cohort of participants were from
the Dietitians in Integrative and Functional Medicine (DIFM) dietary practice group (DPG), a
member group that is part of the Academy of Nutrition and Dietetics (AND). Participants were
asked to fill out a 15-minute online survey to completion. Participants had to be at least 18 years
old, able to read and write in English, and be willing to attempt all parts of the survey. This thesis
project was reviewed and approved by the university’s Institutional Review Board (IRB);
however, it was declared exempt as it did not involve the collection of any identifying data that
could put the participants at risk. The IRB-18-088 letter of exemption and approved email sent to
participants can be found in Appendix A. The target population was healthcare practitioners who
see patients with IBD. The sample for the study was the practitioners who chose to partake in the
survey. We aimed to reach 250 clinicians working with patients with IBD. Participants were
selected as a convenient sample as anyone who the survey was distributed to was allowed to
respond to the survey.
Survey Composition
The survey was created by the student investigator with the help of the thesis committee. The
survey was created on the Qualtrics Experience Management XM survey platform (Qualtrics,
Provo, UT, USA). Qualtrics XM is an online survey software that enables the user with powerful
logic, 100 plus question types, and the ability to reach participants on both mobile devices and
computers. A total of 53 questions were created for the five dietary modalities (Appendix B).
The order for the questions for each dietary modality was as follows:
1. Do you currently recommend (therapeutic) diet?
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2. Approximately what percentage of IBD patients do you recommend (therapeutic) diet to?
3. When you recommend (therapeutic) diet, on average, how would you rate your patients’
ability (self-efficacy) to comply with your recommendation?
4. Among patients who are noncompliant, what are some common barriers?
5. Among the patients who are compliant with diet, when it has been successful, what do
you feel has contributed to its success?
6. For patients who may be eligible, but for whom you don't recommend the diet, please rate
the following:
a. Diet is too restrictive.
b. Diet involves too many changes at once.
c. Cost of food/ingredients is too expensive.
d. Perceived lack of patient interest.
e. Expectation of patient non-adherence.
7. What best represents the reasons you do not recommend (therapeutic) diet?
The survey was a combination of dichotomous, multiple choice, Likert-scale, comment
box open ended, matrix table, and demographic questions. The survey allowed the participant
to input his/her own dietary modality if it was not one of the 5 initially listed. The same 7
questions were then asked of the participant’s input modality. Participants were encouraged
to include any further comments on IBD and diet prior to answering demographic questions.
The survey was sent to multiple external reviewers for validation including two
gastroenterologists and the Academy of Nutrition and Dietetics thesis review board.
Modifications were made based on their feedback.
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Survey Collection
The research team formed a list of contacts who would be helpful in disseminating the
survey. The list of contacts can be found in Appendix C. The list consisted of healthcare
practitioners who the primary researcher and thesis committee believed would fill out the survey,
and also distribute it to their constituents. The list included the president of the Mississippi
Academy of Nutrition and Dietetics, the Chairperson for the Department of Nutrition at
Montclair State University, and the Executive Assistant of the Dietitians in Integrative and
Functional Medicine DPG. The research team reached out to approximately 12 contacts. The
team first contacted the participants via an approved email that can be found in Appendix D. The
email contained a brief explanation of the research and survey, a link to fill out the survey, and
an attached consent form, all which may also be found in Appendix A. The email described both
the nature of the study and the length of the survey. The survey was left open for a period of 9
months. The survey was distributed among the participants from July 1, 2018 to February 14,
2019. One hundred ninety-nine responses were recorded during this time period, however, some
participants were not included in the data analysis due to missing responses.
Data Analysis
Survey responses were coded and entered into the database. Dichotomous variables were
created to determine whether a dietary modality was or was not recommended. The variable
incorporated “have not heard of” and “do not recommend” into one response, and “recommend
occasionally” and “recommend often” into the other. Frequencies were conducted for the
population’s demographics based on this variable and chi-square tests were used to determine
significance. Means ± standard deviations were conducted for the questions targeting
participants’ responses on their patients’ perceived ability to comply with a dietary modality, and
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ANOVA with Duncan’s pairwise comparisons were used to determine significance. Frequencies
were then conducted for the questions targeting participants’ opinions on behavior for each
dietary modality. Chi-square tests were used to determine significant differences among these
opinions about behavior. Results for continuous data are expressed as means ± standard
deviations. Statistical analysis of data was conducted using IBM SPSS statistical software
version 26.0 (SPSS, Chicago, IL, USA) and Microsoft Excel for Mac Version 16.37. All
reported P values were two-tailed and P values of .05 and less were considered statistically
significant.
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CHAPTER IV
RESULTS
Characteristics of the Study Population
The participants’ mean age was 45.1 ± 13.5 years (age range was 24 to 74 years, 115
responses). Females (86.2%) made up most of the sample of the participants who reported their
gender (n = 116). Sixty-five participants did not report their gender. Overall, there were 98 RDs
who responded to the survey (Table 4.1). Other respondents included 8 gastroenterologist
medical doctors, 1 physician’s assistant, 2 nurse practitioners, 1 certified diabetes education, 1
dietetics student, 1 surgeon, and 1 nutrition professional. Sixty-eight participants did not report
their profession. Participants were primarily Caucasian (n = 100, 87.7%). Participants practiced
in a variety of settings including office based solo practices (n = 36, 29.8%), teaching
hospitals/clinics (n = 25, 20.7%), and office based multi-specialty group practices (n = 19,
15.7%). Participants were split between 5 years or less practicing in gastroenterology (n = 46,
46%) and 6 years or more of practice (n = 54, 54%). Participants responded from all regions
throughout the United States, including the south (n = 40, 36.7%) and northeast (n = 37, 33.9%).
There were 181 participants after 18 participants were omitted from the dataset. These 18
participants opened the survey but did not respond to any of the items. Overall, 113 participants
completed every question in the survey. Participant characteristics and their recommendations
for dietary modalities are presented in Tables 4.1 and 4.2.
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Table 4.1

Participants characteristics and the recommendation of general exclusion, low
FODMAPs, and low fiber or low residue diets for IBD.

Characteristicsa

Recommend
or prescribe
general
exclusion diet
occasionally
or often

Do not
recommend or
have not heard
of general
exclusion diet

Age < 35 (n=37)
Age > 36 (n=72)
Women (n=100)
Men (n=16)
Registered
dietitians (n=98)
Gastroenterologist
medical doctors
(n=8)
Practiced 5 years
or less in
gastroenterology
(n=46)
Practiced 6 years
or more in
gastroenterology
(n=54)
Geographical
Region:
Northeast (n=37)
Midwest (n=8)
South (n=40)
West (n=24)

25
42
97
13

Do not
recommend or
have not heard
of low
FODMAPS
diet

12
30
3
3

Recommend
or prescribe
low
FODMAPS
diet
occasionally
or often
23
56
74
5

Do not
recommend or
have not heard
of low fiber or
low residue
diet

14
16
23
8

Recommend
or prescribe
low fiber or
low residue
diet
occasionally
or often
27
53
70
10

63

33

75

21

70

26

7

1

5

2

5

2

26

20

33

13

35

11

34

20

41

13

39

15

22
4
22
17

14
4
17
6

28
4
28
18

8
4
11
5

25
5
33
16

11
3
6
7

a

Numbers of participants differs due to participants not responding to all items.
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10
19
27
3

Table 4.2

Participants characteristics and the recommendation of IgG diet and Specific
Carbohydrate Diet

Characteristicsa

Age < 35 (n=37)
Age > 36 (n=72)
Women (n=100)
Men (n=16)
Registered dietitians
(n=98)
Gastroenterologist
medical doctors (n=8)
Practiced 5 years or
less in
gastroenterology
(n=46)
Practiced 6 years or
more in
gastroenterology
(n=54)
Geographical Region:
Northeast (n=37)
Midwest (n=8)
South (n=40)
West (n=24)

Recommend or
prescribe IgG targeted
exclusion diet
occasionally or often
8
18
22
5

Do not recommend or
have not heard of IgG
targeted exclusion diet
29
54
75
8

Recommend or
prescribe Specific
Carbohydrate Diet
occasionally or often
9
28
30
8

Do not recommend or
have not heard of
Specific Carbohydrate
Diet
28
44
67
5

25

71

31

65

0

7

5

2

13

33

15

31

13

41

22

32

7
3
10
6

29
5
29
17

17
1
10
9

19
7
29
14

a

Numbers of participants differs due to participants not responding to all items.
Dietary Modality Recommendations
Most participants (96.7% of all participants who responded, n = 175) and 98% of RDs (n

= 96) considered using dietary modalities to help treat patients with IBD (P < .001). Significant
differences were found for all participants, and when examining participants who indicated they
were RDs, between recommending or not recommending a dietary modality for all five dietary
modalities (P < .01) Participants in aggregate and “only RDs” were significantly more likely to
recommend the general exclusion diet (P < .01), the low FODMAPs diet (P < .001), and the low
fiber or low residue diet rather than not recommend them to treat patients with IBD (P < .001).
Participants in aggregate and “only RDs” were more likely to not recommend the IgG targeted
exclusion diet or the specific carbohydrate diet rather than recommend them (P < .01). There was
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not a significant difference for recommending or not recommending other “whole-food” based
dietary modalities (P > .05) (Table 4.3).
Table 4.3

Dietary modality recommendations
Dietary modality

All
participantsa

Registered
dietitians

P value

Have you considered using dietary
modalities or modifications to help treat
patients with IBD?
175
96
P < .001
Yes
6
2
No
General exclusion diet:
Recommend occasionally or often
105
63
P < .01
Do not recommend or have not heard of it
63
33
Low FODMAPS diet:
Recommend occasionally or often
83
75
P < .001
Do not recommend or have not heard of it
37
21
Low fiber or low residue diet:
Recommend occasionally or often
95
70
P < .001
Do not recommend or have not heard of it
37
26
IgG mediated exclusion diet:
Recommend occasionally or often
40
25
*P < .001
Do not recommend or have not heard of it
100
71
Specific carbohydrate diet:
Recommend occasionally or often
39
31
*P < .01
Do not recommend or have not heard of it
73
65
Do you currently recommend other
“whole-food” based dietary modalities/
modifications to help treat patients with
P > .05
IBD?
52
46
Yes
60
50
No
a
Numbers of participants differs due to some participants not responding to all items.
*Significant for “diet is not recommended”
Significant at a P value of .05 or less between the variables of recommend or do not
recommend/have not heard of the specific diet using chi-square analysis.
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Ability to Comply with Diets
Registered dietitians perceived that it would be somewhat easy to easy for patients to
comply with the low fiber or low residue diet (mean = 4.2 ± 1.0); none of the dietitians
responded that the low fiber or low residue diet was “very difficult to comply” (Table 4.4). In
comparison, the low FODMAPS and specific carbohydrate diets were rated as somewhat
difficult or difficult to comply (2.7 ± 1.1 and 2.4 ± 1.4, respectively) Overall, the dietitians
perceived that the low fiber/low residue diet was easiest for patients to comply with compared to
the other four diets (P < 0.05). In addition, RDs reported the IgG exclusion diet and the general
exclusion diets were easier to comply with (P<0.05) than the FODMAPS and the specific
carbohydrate diet.
Table 4.4

Registered dietitians’ responses for patients ability to comply with diets.
Mean ± SD
(range of responses*)

Variable
When you recommend a low fiber or low residue diet,
how would you rate your patients' ability (or self4.2 ± 1.1a
efficacy) to comply?
(2 – 6)
When you recommend an IgG targeted exclusion diet,
how would you rate your patients' ability (or self3.3 ± 1.1b
efficacy) to comply?
(2 – 6)
When you recommend a general exclusion diet, how
would you rate your patients' ability (or self-efficacy) to
3.2 ± 1.1b
comply?
(1 – 5)
When you recommend a low FODMAPS diet, how
would you rate your patients' ability (or self-efficacy) to
2.7 ± 1.1c
comply?
(1 – 6)
When you recommend the specific carbohydrate diet,
how would you rate your patients' ability (or self2.4 ± 1.1c
efficacy) to comply?
(1 – 6)
*Responses: 1 = very difficult to comply, 2 = difficult to comply, 3 = somewhat difficult to
comply, 4 = somewhat easy to comply, 5 = easy to comply, 6 = very easy to comply.
abc
Means with different letters are significantly different (P < .05) as determined by ANOVA
using Duncan pairwise comparison
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What Drives Failure/Success
Participants were asked to rate common barriers to patients’ compliance with a diet,
contributors to success with a diet, and why a participant would not recommend a diet for both
eligible and non-eligible patients. Only RDs’ responses were used in the analysis of this data due
to their representing an overwhelming majority of the responses.
Registered dietitians rated several significant notable barriers for patients’ noncompliance to the general exclusion diet including not enough foods to satisfy hunger,
unpalatability of diet, feeling conspicuous among others, and no desire to change (P < .05, Table
4.5). Dietitians did not perceive that the instructions were too difficult (lack of self-efficacy) for
the patients, in addition to the price of food/ingredients, or lack of cooking skills (P > .05). Items
that contributed to success of the general exclusion diet when patients were compliant included
initial consultation with a RD and follow up consultation (P < .001) and that changes were
effective early on and in the long run (P < .001). Dietitians did not feel that changes being
inexpensive or the diet being palatable significantly contributed to its success (P > .05). When
patients were eligible for the general exclusion diet, but the participant did not recommend it,
dietitians agreed that the diet was too restrictive, involved too many changes, or expected patient
non-adherence (P < .001). When participants never recommended the general exclusion diet,
dietitians disagreed that the cost of food was too expensive (P < .001) and disagreed that they did
not have time to cover the diet with their patients (P < .01).
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Table 4.5

Registered dietitians’ barriers, successes, and reasons for not recommending the
general exclusion diet.

Variable
n (%)
P value
Among your patients who are not compliant with a general exclusion diet, what are some
common barriers?
No desire to change
Not a barrier or a slight barrier
40 (63.5)
.032*
Moderate or extreme barrier
23 (36.5)
Instructions are too difficult (lack of self-efficacy)
Not a barrier or a slight barrier
38 (60.3)
.101
Moderate or extreme barrier
25 (39.7)
Price of food/ingredients
Not a barrier or a slight barrier
36 (57.1)
.257
Moderate or extreme barrier
27 (42.9)
Unpalatability of diet
Not a barrier or a slight barrier
42 (66.7)
.008**
Moderate or extreme barrier
21 (33.3)
Not enough foods to satisfy hunger
Not a barrier or a slight barrier
45 (71.4)
.001***
Moderate or extreme barrier
18 (28.6)
Lack of willpower
Not a barrier or a slight barrier
28 (45.2)
.446
Moderate or extreme barrier
34 (54.8)
Requires lengthy preparation
Not a barrier or a slight barrier
28 (45.2)
.446
Moderate or extreme barrier
34 (54.8)
Lack of cooking skills
Not a barrier or a slight barrier
32 (51.6)
.799
Moderate or extreme barrier
30 (48.4)
Feeling conspicuous among others
Not a barrier or a slight barrier
42 (66.7)
.008**
Moderate or extreme barrier
21 (33.3)
Taste preferences among family and friends
Not a barrier or a slight barrier
36 (58.1)
.204
Moderate or extreme barrier
26 (41.9)
Among the patients who are compliant with a general exclusion diet, when it has been
successful, what do you feel has contributed to its success?
Changes were easy or simple to make
Did not contribute or slightly contributed
19 (30.6)
.002**
Moderately or strongly contributed
43 (69.4)
Changes were inexpensive
Did not contribute or slightly contributed
30 (47.6)
.705
Moderately or strongly contribute
33 (52.4)
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Table 4.5 (continued)
Variable
n (%)
P value
Changes were effective early on
Did not contribute or slightly contributed
8 (12.7)
< .001***
Moderately or strongly contributed
55 (87.3)
Changes were effective in the long run
Did not contribute or slightly contributed
7 (11.1)
< .001***
Moderately or strongly contributed
56 (88.9)
Palatability of diet
Did not contribute or slightly contributed
29 (46.0)
.529
Moderately or strongly contributed
34 (54.0)
Instructions were sent home with patient
Did not contribute or slightly contributed
10 (15.9)
< .001***
Moderately or strongly contributed
53 (84.1)
Patient had initial consultation with a registered
dietitian
Did not contribute or slightly contributed
2 (3.2)
< .001***
Moderately or strongly contributed
61 (96.8)
Patient had follow up consultation(s) with a registered
dietitian
Did not contribute or slightly contributed
2 (3.2)
< .001***
Moderately or strongly contributed
61 (96.8)
For patients who may be eligible, but for whom you don't recommend a general exclusion
diet, please rate the following reasons.
Diet is too restrictive
Strongly disagree or disagree
17 (27.0)
< .001***
Agree or strongly agree
46 (73.0)
Diet involves too many changes at once
Strongly disagree or disagree
17 (27.0)
< .001***
Agree or strongly agree
46 (73.0)
Cost of food/ingredients is too expensive
Strongly disagree or disagree
44 (69.8)
.002**
Agree or strongly agree
19 (30.2)
Perceived lack of patient interest
Strongly disagree or disagree
18 (28.6)
.001***
Agree or strongly agree
45 (71.4)
Expectation of patient non-adherence
Strongly disagree or disagree
17 (27.0)
< .001***
Agree or strongly agree
46 (73.0)
What best represents the reasons you do not recommend a general exclusion diet? Please
rate the following reasons.
I don’t have enough knowledge or training
Strongly disagree or disagree
16 (66.7)
.102
Agree or strongly agree
8 (33.3)
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Table 4.5 (continued)
Variable
n (%)
I don’t believe the diet has efficacy
Strongly disagree or disagree
14 (58.3)
Agree or strongly agree
10 41.7)
I don’t have time to cover with patients
Strongly disagree or disagree
19 (79.2)
Agree or strongly agree
5 (20.8)
Lack of evidence or randomized control trials
Strongly disagree or disagree
11 (47.8)
Agree or strongly agree
12 (52.2)
Diet is too restrictive
Strongly disagree or disagree
9 37.5)
Agree or strongly agree
15 (62.5)
Diet involves too many changes at once
Strongly disagree or disagree
15 62.5)
Agree or strongly agree
9 (37.5)
Cost of food/ingredients is too expensive
Strongly disagree or disagree
22 (95.7)
Agree or strongly agree
1 (4.3)
Perceived lack of patient interest
Strongly disagree or disagree
13 (56.5)
Agree or strongly agree
10 (43.5)
Expectation of patient non-adherence
Strongly disagree or disagree
9 (39.1)
Agree or strongly agree
14 (60.9)
*P < .05, **P < .01, ***P < .001 as determined by chi-square analysis.

P value
.414
.004**
.835
.221
.221
< .001***
.532
.297

Registered dietitians rated several significant notable barriers for patients’ noncompliance to the low fiber or low residue diet including instructions are too difficult (lack of
self-efficacy), price of food/ingredients, unpalatability of diet, and requiring lengthy preparation
(P < .001, Table 4.6). Dietitians did not perceive that patients had no desire to change (P > .05).
Items that contributed to success of the low fiber or low residue diet when patients were
compliant included that changes were easy or simple to make, changes were effective early on,
and had an initial consultation and follow up consultation with a registered dietitian (P < .001).
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Dietitians did not feel that the palatability of the diet significantly contributed to its success (P >
.05). When patients were eligible for the low fiber or low residue diet, but the participant did not
recommend it, dietitians disagreed that the diet involved too many changes at once and that the
cost of food/ingredients is too expensive (P < .001). When participants never recommend the low
fiber or low residue diet, dietitians agreed they did not believe the diet has efficacy (P < .05) and
disagreed that they did not have enough knowledge or training (P < .001).
Table 4.6

Registered dietitians’ barriers and reasons for not recommending the low fiber or
low residue diet.

Variable
n (%)
P value
Among your patients who are not compliant with a low fiber or low residue diet, what are
some common barriers?
No desire to change
Not a barrier or a slight barrier
37 (52.9)
.633
Moderate or extreme barrier
33 (47.1)
Instructions are too difficult (lack of self-efficacy)
Not a barrier or a slight barrier
55 (78.6)
< .001***
Moderate or extreme barrier
15 (21.4)
Price of food/ingredients
Not a barrier or a slight barrier
65 (92.9)
< .001***
Moderate or extreme barrier
5 (7.1)
Unpalatability of diet
Not a barrier or a slight barrier
50 (71.4)
< .001**
Moderate or extreme barrier
20 (28.6)
Not enough foods to satisfy hunger
Not a barrier or a slight barrier
54 (77.1)
< .001***
Moderate or extreme barrier
16 (22.9)
Lack of willpower
Not a barrier or a slight barrier
47 (67.1)
.004**
Moderate or extreme barrier
23 (32.9)
Requires lengthy preparation
Not a barrier or a slight barrier
60 (85.7)
< .001***
Moderate or extreme barrier
10 (14.3)
Lack of cooking skills
Not a barrier or a slight barrier
48 (68.6)
.002**
Moderate or extreme barrier
22 (31.4)
Feeling conspicuous among others
Not a barrier or a slight barrier
51 (72.9)
< .001***
Moderate or extreme barrier
19 (27.1)
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Table 4.6 (continued)
Variable
n (%)
P value
Taste preferences among family and friends
Not a barrier or a slight barrier
44 (62.9)
.031*
Moderate or extreme barrier
26 (37.1)
Among the patients who are compliant with a low fiber or low residue diet, when it has
been successful, what do you feel has contributed to its success?
Changes were easy or simple to make
Did not contribute or slightly contributed
11 (15.7)
< .001**
Moderately or strongly contributed
59 (84.3)
Changes were inexpensive
Did not contribute or slightly contributed
23 (32.9)
.004**
Moderately or strongly contribute
47 (67.1)
Changes were effective early on
Did not contribute or slightly contributed
10 (14.3)
< .001***
Moderately or strongly contributed
60 (85.7)
Changes were effective in the long run
Did not contribute or slightly contributed
19 (27.1)
< .001***
Moderately or strongly contributed
51 (72.9)
Palatability of diet
Did not contribute or slightly contributed
31 (44.3)
.339
Moderately or strongly contributed
39 (55.7)
Instructions were sent home with patient
Did not contribute or slightly contributed
15 (21.4)
< .001***
Moderately or strongly contributed
55 (78.6)
Patient had initial consultation with a registered
dietitian
Did not contribute or slightly contributed
3 (4.3)
< .001***
Moderately or strongly contributed
67 (95.7)
Patient had follow up consultation(s) with a registered
dietitian
Did not contribute or slightly contributed
6 (8.6)
< .001***
Moderately or strongly contributed
64 (91.4)
For patients who may be eligible, but for whom you don't recommend a low fiber or low
residue diet, please rate the following reasons.
Diet is too restrictive
Strongly disagree or disagree
49 (70.0)
.001***
Agree or strongly agree
21 (30.0)
Diet involves too many changes at once
Strongly disagree or disagree
51 (72.9)
< .001***
Agree or strongly agree
19 (27.1)
Cost of food/ingredients is too expensive
Strongly disagree or disagree
63 (90.0)
< .001***
Agree or strongly agree
7 (10.0)
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Table 4.6 (continued)
Variable
n (%)
P value
Perceived lack of patient interest
Strongly disagree or disagree
34 (48.6)
.811
Agree or strongly agree
36 (51.4)
Expectation of patient non-adherence
Strongly disagree or disagree
34 (48.6)
.811
Agree or strongly agree
36 (51.4)
What best represents the reasons you do not recommend a low fiber or low residue diet?
Please rate the following reasons.
I don’t have enough knowledge or training
Strongly disagree or disagree
21 (87.5)
< .001***
Agree or strongly agree
3 (12.5)
I don’t believe the diet has efficacy
Strongly disagree or disagree
6 (25.0)
.014*
Agree or strongly agree
18 (75.0)
I don’t have time to cover with patients
Strongly disagree or disagree
23 (100)
n/a
Agree or strongly agree
0 (0)
Lack of evidence or randomized control trials
Strongly disagree or disagree
11 (47.8)
.835
Agree or strongly agree
12 (52.2)
Diet is too restrictive
Strongly disagree or disagree
13 (56.5)
.532
Agree or strongly agree
10 (43.5)
Diet involves too many changes at once
Strongly disagree or disagree
17 (73.9)
.022*
Agree or strongly agree
6 (26.1)
Cost of food/ingredients is too expensive
Strongly disagree or disagree
22 (95.7)
< .001***
Agree or strongly agree
1 (4.3)
Perceived lack of patient interest
Strongly disagree or disagree
18 (78.3)
.007**
Agree or strongly agree
5 (21.7)
Expectation of patient non-adherence
Strongly disagree or disagree
17 (73.9)
.022*
Agree or strongly agree
6 (26.1)
*P < .05, **P < .01, ***P < .001 as determined by chi-square analysis. n/a (not available), test
cannot be performed with 0 cases.
Registered dietitians rated several significant notable barriers for patients’ noncompliance to the low FODMAPS diet including instructions are too difficult (lack of self44

efficacy) and not enough foods to satisfy hunger (P < .01, Table 4.7), as well as unpalatability of
diet and price of food/ingredients (P < .001). Dietitians did not perceive lack of cooking skills or
feeling conspicuous among others as notable barriers to compliance with the low FOMDMAPS
diet. Items that contributed to success of the low FODMAPS diet when patients were compliant
included instructions were sent home with the patient, an initial and follow up consultation with
a registered dietitian, and changes were effective early on and in the long run (P < .001). When
patients were eligible for the low FODMAPS diet, but the participant did not recommend it,
dietitians agreed that the diet involved too many changes at once (P < .001) and the diet was too
restrictive (P < .01). Dietitians did not feel the expense of food or ingredients influenced their
recommendation. When participants never recommended the low FODMAPS diet, the only
significant reason participants disagreed with was not having time to cover the diet with the
patients (P < .001).
Table 4.7

Registered dietitians’ barriers, successes, and reasons for not recommending the
low FODMAPS diet.

Variable
n (%)
P value
Among your patients who are not compliant with a low FODMAPS diet, what are some
common barriers?
No desire to change
Not a barrier or a slight barrier
45 (60.8)
.063
Moderate or extreme barrier
29 (39.2)
Instructions are too difficult (lack of self-efficacy)
Not a barrier or a slight barrier
24 (32.0)
.002**
Moderate or extreme barrier
51 (68.0)
Price of food/ingredients
Not a barrier or a slight barrier
53 (71.6)
< .001***
Moderate or extreme barrier
21 (28.4)
Unpalatability of diet
Not a barrier or a slight barrier
52 (70.3)
< .001**
Moderate or extreme barrier
22 (29.7)
Not enough foods to satisfy hunger
Not a barrier or a slight barrier
48 (64.9)
.011*
Moderate or extreme barrier
26 (35.1)
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Table 4.7 (continued)
Variable

n (%)

P value

Lack of willpower
Not a barrier or a slight barrier
33 (45.2)
.413
Moderate or extreme barrier
40 (54.8)
Requires lengthy preparation
Not a barrier or a slight barrier
33 (45.2)
.413
Moderate or extreme barrier
40 (54.8)
Lack of cooking skills
Not a barrier or a slight barrier
38 (51.4)
.816
Moderate or extreme barrier
36 (48.6)
Feeling conspicuous among others
Not a barrier or a slight barrier
38 (51.4)
.816
Moderate or extreme barrier
36 (48.6)
Taste preferences among family and friends
Not a barrier or a slight barrier
34 (45.9)
.485
Moderate or extreme barrier
40 (54.1)
Among the patients who are compliant with a low FODMAPS diet, when it has been
successful, what do you feel has contributed to its success?
Changes were easy or simple to make
Did not contribute or slightly contributed
37 (49.3)
.908
Moderately or strongly contributed
38 (50.7)
Changes were inexpensive
Did not contribute or slightly contributed
45 (60.8)
.063
Moderately or strongly contribute
29 (39.2)
Changes were effective early on
Did not contribute or slightly contributed
9 (12.2)
< .001***
Moderately or strongly contributed
65 (87.8)
Changes were effective in the long run
Did not contribute or slightly contributed
9 (12.2)
< .001***
Moderately or strongly contributed
65 (87.8)
Palatability of diet
Did not contribute or slightly contributed
36 (48.0)
.729
Moderately or strongly contributed
39 (52.0)
Instructions were sent home with patient
Did not contribute or slightly contributed
7 (9.3)
< .001***
Moderately or strongly contributed
68 (90.7)
Patient had initial consultation with a registered
dietitian
Did not contribute or slightly contributed
2 (2.7)
< .001***
Moderately or strongly contributed
73 (97.3)
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Table 4.7 (continued)
Variable
n (%)
P value
Patient had follow up consultation(s) with a registered
dietitian
Did not contribute or slightly contributed
2 (2.7)
< .001***
Moderately or strongly contributed
73 (97.3)
For patients who may be eligible, but for whom you don't recommend a low FODMAPS
diet, please rate the following reasons.
Diet is too restrictive
Strongly disagree or disagree
24 (32.9)
.003**
Agree or strongly agree
49 (67.1)
Diet involves too many changes at once
Strongly disagree or disagree
15 (20.3)
< .001***
Agree or strongly agree
59 (79.7)
Cost of food/ingredients is too expensive
Strongly disagree or disagree
57 (77.0)
< .001***
Agree or strongly agree
17 (23.0)
Perceived lack of patient interest
Strongly disagree or disagree
28 (37.8)
.036*
Agree or strongly agree
46 (62.2)
Expectation of patient non-adherence
Strongly disagree or disagree
26 (35.1)
.011*
Agree or strongly agree
48 (64.9)
What best represents the reasons you do not recommend a low FODMAPS diet? Please
rate the following reasons.
I don’t have enough knowledge or training
Strongly disagree or disagree
11 (61.1)
.346
Agree or strongly agree
7 (38.9)
I don’t believe the diet has efficacy
Strongly disagree or disagree
11 (61.1)
.346
Agree or strongly agree
7 (38.9)
I don’t have time to cover with patients
Strongly disagree or disagree
16 (88.9)
.001***
Agree or strongly agree
2 (11.1)
Lack of evidence or randomized control trials
Strongly disagree or disagree
6 (33.3)
.157
Agree or strongly agree
12 (66.7)
Diet is too restrictive
Strongly disagree or disagree
7 (38.9)
.346
Agree or strongly agree
11 (61.1)
Diet involves too many changes at once
Strongly disagree or disagree
7 (38.9)
.346
Agree or strongly agree
11 (61.1)
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Table 4.7 (continued)
Variable
n (%)
Cost of food/ingredients is too expensive
Strongly disagree or disagree
11 (61.1)
Agree or strongly agree
7 (38.9)
Perceived lack of patient interest
Strongly disagree or disagree
10 (55.6)
Agree or strongly agree
8 (44.4)
Expectation of patient non-adherence
Strongly disagree or disagree
6 (33.3)
Agree or strongly agree
12 (66.7)
*P < .05, **P < .01, ***P < .001 as determined by chi-square analysis.

P value
.346
.637
.157

Registered dietitians rated several significant notable barriers for patients’ noncompliance to the IgG targeted exclusion diet including unpalatability of diet (P < .01, Table 4.8)
and not enough foods to satisfy hunger (P < .05). Dietitians did not perceive taste preferences
among family and friends or no desire to change as significant barriers (P > .05). Items that
contributed to success of the IgG targeted exclusion diet when patients were compliant included
instructions being sent home with the patient, changes being effective early on, and changes
being effective in the long run (P < .001). One hundred percent of participants felt an initial and
follow up consultation contributed moderately or strongly to the success of the diet. When
patients were eligible for the IgG targeted exclusion diet, but the participant did not recommend
it, dietitians agreed there was a perceived lack of patient interest (P < .01). When participants
never recommended the IgG targeted exclusion diet, participants agreed there was a lack of
evidence or randomized control trials (P < .001).
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Table 4.8

Registered dietitians’ barriers, successes, and reasons for not recommending the
IgG targeted exclusion diet.

Variable
n (%)
P value
Among your patients who are not compliant with an IgG targeted exclusion diet, what are
some common barriers?
No desire to change
Not a barrier or a slight barrier
12 (48.0)
.841
Moderate or extreme barrier
13 (52.0)
Instructions are too difficult (lack of self-efficacy)
Not a barrier or a slight barrier
16 (64.0)
.162
Moderate or extreme barrier
9 (36.0)
Price of food/ingredients
Not a barrier or a slight barrier
17 (68.0)
.072
Moderate or extreme barrier
8 (32.0)
Unpalatability of diet
Not a barrier or a slight barrier
19 (76.0)
.009**
Moderate or extreme barrier
6 (24.0)
Not enough foods to satisfy hunger
Not a barrier or a slight barrier
18 (72.0)
.028*
Moderate or extreme barrier
7 (28.0)
Lack of willpower
Not a barrier or a slight barrier
8 (32.0)
.072
Moderate or extreme barrier
17 (68.0)
Requires lengthy preparation
Not a barrier or a slight barrier
15 (60.0)
.317
Moderate or extreme barrier
10 (40.0)
Lack of cooking skills
Not a barrier or a slight barrier
15 (60.0)
.317
Moderate or extreme barrier
10 (40.0)
Feeling conspicuous among others
Not a barrier or a slight barrier
17 (68.0)
.072
Moderate or extreme barrier
8 (32.0)
Taste preferences among family and friends
Not a barrier or a slight barrier
13 (52.0)
.841
Moderate or extreme barrier
12 (48.0)
Among the patients who are compliant with an IgG targeted exclusion diet, when it has
been successful, what do you feel has contributed to its success?
Changes were easy or simple to make
Did not contribute or slightly contributed
7 (28.0)
.028*
Moderately or strongly contributed
18 (72.0)
Changes were inexpensive
Did not contribute or slightly contributed
12 (48.0)
.841
Moderately or strongly contribute
13 (52.0)
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Table 4.8 (continued)
Variable
n (%)
P value
Changes were effective early on
Did not contribute or slightly contributed
1 (4.0)
< .001***
Moderately or strongly contributed
24 (96.0)
Changes were effective in the long run
Did not contribute or slightly contributed
2 (8.0)
< .001***
Moderately or strongly contributed
23 (92.0)
Palatability of diet
Did not contribute or slightly contributed
9 (36.0)
.162
Moderately or strongly contributed
16 (64.0)
Instructions were sent home with patient
Did not contribute or slightly contributed
1 (4.0)
< .001***
Moderately or strongly contributed
24 (96.0)
Patient had initial consultation with a registered
dietitian
Did not contribute or slightly contributed
0 (0)
n/a
Moderately or strongly contributed
25 (100)
Patient had follow up consultation(s) with a registered
dietitian
Did not contribute or slightly contributed
0 (0)
n/a
Moderately or strongly contributed
25 (100)
For patients who may be eligible, but for whom you don't recommend an IgG targeted
exclusion diet, please rate the following reasons.
Diet is too restrictive
Strongly disagree or disagree
11 (44.0)
.549
Agree or strongly agree
14 (56.0)
Diet involves too many changes at once
Strongly disagree or disagree
10 (40.0)
.317
Agree or strongly agree
15 (60.0)
Cost of food/ingredients is too expensive
Strongly disagree or disagree
20 (80.0)
.003**
Agree or strongly agree
5 (20.0)
Perceived lack of patient interest
Strongly disagree or disagree
6 (24.0)
.009**
Agree or strongly agree
19 (76.0)
Expectation of patient non-adherence
Strongly disagree or disagree
8 (32.0)
.072
Agree or strongly agree
17 (68.0)
What best represents the reasons you do not recommend an IgG targeted exclusion diet?
Please rate the following reasons.
I don’t have enough knowledge or training
Strongly disagree or disagree
30 (65.2)
.039*
Agree or strongly agree
16 (34.8)
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Table 4.8 (continued)
Variable
n (%)
P value
I don’t believe the diet has efficacy
Strongly disagree or disagree
12 (28.6)
.005**
Agree or strongly agree
30 (71.4)
I don’t have time to cover with patients
Strongly disagree or disagree
38 (90.5)
< .001***
Agree or strongly agree
4 (9.5)
Lack of evidence or randomized control trials
Strongly disagree or disagree
9 (21.4)
< .001***
Agree or strongly agree
33 (78.6)
Diet is too restrictive
Strongly disagree or disagree
29 (69.0)
.014*
Agree or strongly agree
13 (31.0)
Diet involves too many changes at once
Strongly disagree or disagree
30 (71.4)
.005**
Agree or strongly agree
12 (28.6)
Cost of food/ingredients is too expensive
39 (92.9)
< .001***
Strongly disagree or disagree
3 (7.1)
Agree or strongly agree
Perceived lack of patient interest
Strongly disagree or disagree
34 (81.0)
< .001***
Agree or strongly agree
8 (19.0)
Expectation of patient non-adherence
Strongly disagree or disagree
31 (73.8)
.002**
Agree or strongly agree
11 (26.2)
*P < .05, **P < .01, ***P < .001 as determined by chi-square analysis. n/a: not able to calculate
due to zero cases in one category.
Registered dietitians rated several significant notable barriers for patients’ noncompliance to the SCD including instructions are too difficult (lack of self-efficacy) and taste
preferences among family and friends (P < .05, Table 4.9). Dietitians did not perceive lack of
willpower or unpalatability of diet as significant barriers (P > .05). Items that contributed to
success of the SCD when patients were compliant included changes being effective early on and
in the long run, and initial and follow up consultations with a registered dietitian (P < .001).
When patients were eligible for the SCD but the participant did not recommend it, dietitians
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agreed that the diet is too restrictive (P < .001), the diet involved too many changes at once (P =
.001), and there was a perceived lack of patient interest (P = .001). When participants never
recommended the SCD, participants disagreed that the cost of food/ingredients was too
expensive or that they did not have enough time to cover the diet with their patients (P < .001).
Table 4.9

Registered dietitians’ barriers, successes, and reasons for not recommending the
Specific Carbohydrate Diet.

Variable
n (%)
P value
Among your patients who are not compliant with the specific carbohydrate diet, what are
some common barriers?
No desire to change
Not a barrier or a slight barrier
17 (56.7)
.465
Moderate or extreme barrier
13 (43.3)
Instructions are too difficult (lack of self-efficacy)
Not a barrier or a slight barrier
9 (30.0)
.028*
Moderate or extreme barrier
21 (70.0)
Price of food/ingredients
Not a barrier or a slight barrier
18 (60.0)
.273
Moderate or extreme barrier
12 (40.0)
Unpalatability of diet
Not a barrier or a slight barrier
13 (43.3)
.465
Moderate or extreme barrier
17 (56.7)
Not enough foods to satisfy hunger
Not a barrier or a slight barrier
12 (40.0)
.273
Moderate or extreme barrier
18 (60.0)
Lack of willpower
Not a barrier or a slight barrier
13 (43.3)
.465
Moderate or extreme barrier
17 (56.7)
Requires lengthy preparation
Not a barrier or a slight barrier
10 (33.3)
.068
Moderate or extreme barrier
20 (66.7)
Lack of cooking skills
Not a barrier or a slight barrier
12 (40.0)
.273
Moderate or extreme barrier
18 (60.0)
Feeling conspicuous among others
Not a barrier or a slight barrier
11 (36.7)
.144
Moderate or extreme barrier
19 (63.3)
Taste preferences among family and friends
Not a barrier or a slight barrier
9 (30.0)
.028*
Moderate or extreme barrier
21 (70.0)
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Table 4.9 (continued)
Variable
n (%)
P value
Among the patients who are compliant with the specific carbohydrate diet, when it has
been successful, what do you feel has contributed to its success?
Changes were easy or simple to make
Did not contribute or slightly contributed
16 (53.3)
.715
Moderately or strongly contributed
14 (46.7)
Changes were inexpensive
Did not contribute or slightly contributed
19 (63.3)
.144
Moderately or strongly contribute
11 (36.7)
Changes were effective early on
Did not contribute or slightly contributed
5 (16.7)
< .001***
Moderately or strongly contributed
25 (83.3)
Changes were effective in the long run
Did not contribute or slightly contributed
3 (10.0)
< .001***
Moderately or strongly contributed
27 (90.0)
Palatability of diet
Did not contribute or slightly contributed
14 (46.7)
.715
Moderately or strongly contributed
16 (53.3)
Instructions were sent home with patient
Did not contribute or slightly contributed
4 (13.3)
< .001***
Moderately or strongly contributed
26 (86.7)
Patient had initial consultation with a registered
dietitian
Did not contribute or slightly contributed
1 (3.3)
< .001***
Moderately or strongly contributed
29 (96.7)
Patient had follow up consultation(s) with a registered
dietitian
Did not contribute or slightly contributed
2 (6.7)
< .001***
Moderately or strongly contributed
28 (93.3)
For patients who may be eligible, but for whom you don't recommend the specific
carbohydrate diet, please rate the following reasons.
Diet is too restrictive
Strongly disagree or disagree
5 (16.7)
< .001***
Agree or strongly agree
25 (83.3)
Diet involves too many changes at once
Strongly disagree or disagree
6 (20.0)
.001***
Agree or strongly agree
24 (80.0)
Cost of food/ingredients is too expensive
Strongly disagree or disagree
17 (56.7)
.465
Agree or strongly agree
13 (43.3)
Perceived lack of patient interest
Strongly disagree or disagree
6 (20.0)
.001***
Agree or strongly agree
24 (80.0)
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Table 4.9 (continued)
Variable
n (%)
P value
Expectation of patient non-adherence
Strongly disagree or disagree
8 (26.7)
.011*
Agree or strongly agree
22 (73.3)
What best represents the reasons you do not recommend the specific carbohydrate diet?
Please rate the following reasons.
I don’t have enough knowledge or training
Strongly disagree or disagree
23 (46.0)
.572
Agree or strongly agree
27 (54.0)
I don’t believe the diet has efficacy
Strongly disagree or disagree
28 (57.1)
.317
Agree or strongly agree
21 (42.9)
I don’t have time to cover with patients
Strongly disagree or disagree
46 (93.9)
< .001***
Agree or strongly agree
3 (6.1)
Lack of evidence or randomized control trials
Strongly disagree or disagree
20 (41.7)
.248
Agree or strongly agree
28 (58.3)
Diet is too restrictive
Strongly disagree or disagree
26 (53.1)
.668
Agree or strongly agree
23 (46.9)
Diet involves too many changes at once
Strongly disagree or disagree
21 (43.8)
.386
Agree or strongly agree
27 (56.3)
Cost of food/ingredients is too expensive
Strongly disagree or disagree
38 (79.2)
< .001***
Agree or strongly agree
10 (20.8)
Perceived lack of patient interest
Strongly disagree or disagree
27 (55.1)
.475
Agree or strongly agree
22 (44.9)
Expectation of patient non-adherence
Strongly disagree or disagree
22 (44.9)
.475
Agree or strongly agree
27 (55.1)
*P < .05, **P < .01, ***P < .001 as determined by chi-square analysis.
Differences in Geographical Location, Age, and Years of Practice
Statistical analysis was conducted comparing geographical locations for each diet. When
separated by highest populated vs lowest populated states in the United States according to
worldatlas.com, significant differences were only found when recommending a general exclusion
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diet (37 participants vs 28, P = .022). Participants in the highest populated states tended to
recommend a general exclusion diet more often than participants in the lowest populated states.
Statistical analysis was also conducted comparing the age of the participants who were between
ages 18 and 35 and those who were 36 and older. No significant differences were observed
across each diet. Similarly, no significant differences were found when comparing participants
who practiced for 5 years or less vs greater than 5 years.
Diet Mentioned By Multiple Practitioners
Participants had the option of inputting any diet into the survey and answering the same
set of questions that were asked of the 5 previous diets. One diet that was suggested by 11
participants was the Lifestyle Eating and Performance (LEAP) protocol. Seven of the 11
participants believed compliance with the LEAP protocol was either easy or somewhat easy.
Only 3 of the 11 participants felt a notable barrier to the LEAP protocol was a lack of selfefficacy. Ten of the 11 participants did not feel the LEAP protocol lacked foods to satisfy
hunger. All 11 participants felt that changes being effective early on and in the long run
contributed to its success, and all 11 participants felt an initial and follow up consultation
strongly contributed as well. Eight of 11 participants felt that instructions being sent home with
the participants contributed strongly to its success. When participants were eligible for the
LEAP, protocol but participants did not recommend it, 9 agreed they did not recommend it based
on the expectation of patient non-adherence or the perceived lack of patient interest.
Practitioner Opinions on Diet and IBD
Participants were offered the option of providing additional information or opinions
about the role of diet and nutrition as a treatment for IBD. Many provided interesting answers.
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An RD practicing at a teaching hospital uses pureed foods with fiber included in the IBD-AID
based on the fact that it is a prebiotic, an important source of nutrients for the immune system,
and is tolerated well by a sensitive gut. An RD at an office based solo practice states that
nutrition interventions should be considered as a primary intervention. A gastroenterologist at an
office based single specialty group practice stated that a low residue diet is preferred for patients
with strictures who are at a high risk for obstruction, and not to treat inflammation. Another RD
at an office based solo practice stated that diet recommendations based on hypersensitivity
reactions determined through a blood test seem to have the best results.
A gastroenterologist at a teaching hospital/clinic self-identified barriers as lack of time to
teach patients about diet, lack of access to a RD, and a lack of convincing clinical trial data to
motivate the use of these diets. The gastroenterologist does enroll patients in a clinical SCD trial.
A RD at a non-profit specialty clinic for behavioral health and eating disorders identified the
need for more collaboration/communication between the primary care physician, RD, and
gastroenterologist for patients with IBD. The RDs clients complain of mixed messaging from the
various providers. The RD states that the RD should always ask for a Release of Information and
try to collaborate with other health professionals since the RD is most likely to see the patient
most often. The RD can then offer feed back to the other professionals to reduce time,
frustration, and cost for all involved.
An RD at a non-profit hospital recommends including omega-3 and antioxidant rich
foods with an emphasis on food sources of healthy bacteria, and a high protein/low fiber diet
with a calorie goal to limit or avoid weight loss for patients in a flare. A nurse practitioner at an
office based single specialty practice group states more research is needed in the area and is
excited to see more data on diet-based therapy outcomes in IBD. A physician’s assistant states
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that diet therapy should be considered a compliment to the patient’s medical therapy, and that
patients with moderate to severe IBD need to be encouraged to continue medical therapy while
exploring diet modifications. The physician’s assistant also states that IBD practices need RDs to
help educate and reinforce therapy because there is not enough time for other providers to
properly educate their patients.
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CHAPTER V
DISCUSSION
There are many different types of dietary interventions available to help manage
symptoms or induce clinical remission in patients with IBD, and several are becoming
increasingly popular. These diets generally restrict certain foods or food groups that are proposed
to cause either IBD or its symptoms. The five diets chosen for this study all show initial efficacy
in a variety of research designs, however large RCTs are needed to develop firm and convincing
recommendations. The challenge with RCTs is the required length of participation for IBD
patients due to the chronic nature of the disease.
The most thoroughly studied intervention is EN. Unfortunately, while this method holds
efficacy52, it severely restricts IBD patient’s ability to live a normal lifestyle as it pertains to
consuming regular meals. While enteral nutrition is commonly used as a first line of treatment
for patients with IBD52, it was not mentioned by any of the participants as their input was
requested on “whole-food” based diets, not supplements or non-oral nutrition.
In this study healthcare practitioners were surveyed on their viewpoints of different
dietary modalities used in the management of IBD. The 5 initial diets included in the survey
were the general exclusion diet, low fiber or low residue diet, low FODMAPs diet, IgG targeted
exclusion diet, and SCD. Gastroenterologists, physician’s assistants, nurse practitioners,
registered dietitians and other healthcare practitioners were included in the survey.
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One hundred eighty-one participants at least partially completed the survey. Most participants
did not respond to every item, especially the questions about some specific diets. Perhaps they
were not familiar with some of the diets and were not comfortable responding. Participants
represented a wide variety of geographical locations, areas of practice, and experience. The vast
majority of participants (96.7%) considered using dietary modalities to help treat patients with
IBD.
A previous study found that 48% of IBD patients believed diet initiates disease, 57%
believed diet triggers relapse, 50% of patients received no nutrition advice from their healthcare
providers, and 67% wanted more advice.51 Forty-five percent of IBD patients wanted this advice
to be from a RD.51 This aligns with the data collected in our survey, since across all 5 diets RDs
believed that an initial and follow up consultation from a RD greatly contributed to a patient’s
success with a diet. Greater involvement from RDs is key to helping patients modify their diet
successfully.
Low Fiber or Low Residue Diet
Low fiber or low residue diets are recommended for IBD patients with severe
inflammation and bowel strictures, although significant differences may not exist.64 Significantly
more health care practitioners recommended a low fiber/low residue diet occasionally or often
compared to those who do not. A low fiber/low residue diet was also rated as easiest in terms of
compliance in the present study. Registered dietitians did not feel that a lack of self-efficacy was
a barrier. Most dietitians (84.3%) agreed that changes being easy to make contributed moderately
or strongly to the success with the diet. Changes being effective early on, changes being effective
in the long run, and instructions being sent home with the patient all also moderately or strongly
contributed to patient success with the diet according to RDs. A majority of RDs (85.7%) did not
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feel lengthy preparation was a moderate or extreme barrier to compliance. This all most likely
contributed to the ease of compliance. Lower consumption of insoluble fiber and residue most
likely decreases the incidence of functional bowel symptoms in IBD patients, and a quick
resolution of this contributes to the diet’s perceived success. One significant reason RDs did not
recommend a low fiber diet was because they did not believe the diet had efficacy. While RDs
do recommend this diet, there is risk associated with not consuming fiber due to its impact on gut
heatlh.64,65 A low fiber/ low residue diet may not be the answer as a lifelong modality to follow
for IBD patients, however with proper guidance from a RD, it may help to manage the symptoms
of patients with a severe flare. More in-depth RCTs are warranted with the low fiber/low residue
and IBD patients.
General Exclusion Diet
A general exclusion diet is commonly used to identify foods that exacerbate symptoms,
especially during flares.76 In total, a significant number of participants (105) recommend the
general exclusion diet occasionally or often. The diet had a mean response of 3.2 ± 1.1 for the
patients’ ability to comply with the diet, indicating it was between ‘somewhat difficult’ to
‘somewhat easy’ to comply. Several common barriers that achieved significance for the general
exclusion diet were reported by participants. Most RDs (71.4%) felt not enough foods to satisfy
hunger was either not a barrier or only a slight barrier, and 66.7% thought unpalatability of the
diet was not a barrier or only a slight barrier. Significant contributors to patient success with the
diet include changes being effective early on and in the long run, and an initial and follow up
consultation with a RD. This data supports the conclusion drawn when comparing the
carbohydrate, fiber rich diet to a general exclusion diet, that intense cooperation between
patients, doctors, and dietitians is necessary for patient success.76 The general exclusion diet
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seems to be one that shows promise because of its ability to be adapted on a case by case basis
for each patient. Since specific foods are being identified that exacerbate symptoms, any foods
that do not exacerbate symptoms are allowed. This would seem to allow enough foods to satisfy
hunger. The number of foods that are allowed also fuel the palatability of the diet. Twenty-two of
the 23 registered dietitians who rated cost of food being too expensive disagreed or strongly
disagreed with this notion as a basis for not recommending the diet. All of these reasons indicate
that the general exclusion diet has potential in IBD patients and warrants further study.
Low FODMAPS Diet
The low FODMAPS diet attempts to eliminate certain oligosaccharides that cause
functional bowel symptoms.64 While symptom improvement may occur, there is a lack of
convincing evidence on the diet decreasing inflammation in IBD patients. A significant number
of total participants (83) and RDs (75) recommended a low FODMAPS diet occasionally or
often. However, RDs rated their patients’ ability to comply with the diet as somewhat difficult to
difficult. Sixty-eight percent of RDs rated the instructions as too difficult (lack of self-efficacy)
and was a significant barrier to patient compliance. When the diet was successful, RDs rated
changes being effective early on and in the long run as significant contributors, as well as initial
and follow up consultations with a RD, and instructions being sent home with the patient. When
patients were eligible, but the diet was not recommended, 79.7% of dietitians felt the diet
involved too many changes at once, 67.1% felt the diet was too restrictive, and 64.9% suspected
significant patient non-adherence. The low FODMAPS dietary modality shows promise in
resolving IBD patients’ symptoms. Compliance with the diet is the number one issue, and some
dietitians do not recommend this diet because it is too restrictive or too involved. It seems
imperative that a RD is involved when attempting the low FODMAPS diet, especially since a
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carbohydrate restricted diet may lead to certain vitamin and mineral deficiencies, as well as
insufficient calorie intake and weight loss.64 It will be interesting to further understand how
much the resolution of symptoms can drive patient compliance, and future studies on the low
FODMAPS diet in the IBD population is needed. Interestingly, a national survey reported that
505 of 1,468 gastroenterologists “usually recommended” a low FODMAPS diet for their IBS
patients.90 The study also indicated that only 21% of the doctors “usually” or “almost always”
referred their IBS patients to a RD.90
IgG Targeted Exclusion Diet
The IgG targeted exclusion diet attempts to identify foods that should be avoided based
on the production of IgG antibodies via blood testing.69 Only 40 out of 140 participants
recommended an IgG targeted exclusion diet occasionally or often. This is interesting
considering the patients’ ability to comply with the diet as rated as 3.4 ± 1.0, indicating that
compliance with the diet is between somewhat difficult to somewhat easy. This also makes it the
second easiest diet in regard to perceived patient compliance. Twenty-four percent of RDs felt
the unpalatability of the diet was a significant barrier to patient compliance and 28% felt there
were not enough foods to satisfy hunger. Reasons that contributed to the success of the diet
include changes being effective early on and in the long run, as well as instructions being sent
home with the patient. When patients were eligible, but the diet was not recommended, the only
significant reason dietitians agreed with was perceived lack of patient interest. Most RDs
(71.4%) who did not recommend the diet did not believe the diet had efficacy, and 78.6%
believed there was a lack of evidence or RCTs to support its use. The participants viewpoints of
the IgG targeted exclusion diet present interesting results. A large number of participants did not
recommend the diet, however, ones who did evaluated compliance as the second easiest among
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the diets surveyed. Since compliance was perceived as relatively easy, and the reason for not
recommending the diet was due to a lack of evidence, well-designed RCTs on patients with IBD
and the IgG targeted exclusion diet is warranted.
Specific Carbohydrate Diet
The Specific Carbohydrate Diet is a carbohydrate restricted diet that is high in protein,
fat, fruits, amylose containing vegetables, and nuts, while eliminating grains, lactose, and
processed sugar.94 Only 39 participants recommended the Specific Carbohydrate Diet
occasionally or often. The diet was also rated lowest in terms of ease of compliance at 2.4 ± 1.4,
indicating it is somewhat difficult to difficult. The perceived compliance matches well with the
previous literature on the diet, since proponents of the diet recommended using it for at least one
year.64 Seventy percent of dietitians felt that instructions being too difficult and taste preferences
among family and friends are moderate or extreme barriers to patient compliance. However,
when the diet was successful, changes being effective early on and in the long run moderately or
strongly contributed to its success. Similar to the other 5 diets, initial and follow up consultations
significantly contributed to patient success with the diet. When patients were eligible, but
dietitians did not recommend the diet, 83.3% significantly agreed the diet was too restrictive,
80% agreed it involved too many changes at once, and 80% agreed there was a perceived lack of
patient interest. The Specific Carbohydrate Diet has a limited but increasing body of evidence
supporting its use in IBD patients. Pediatric patients especially may benefit from a diet that can
provide both symptomatic and clinical relief.75,96 The difficulty with compliance might be solved
by greater involvement from a RD. Randomized control trials are necessary to better determine
the efficacy of the Specific Carbohydrate Diet.
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Further Provider Input on Diet and IBD
The information provided when answering the question about anything else the
participants wanted to state about diet and IBD helped to shed light on what needs to be done to
advance the use of diet as a management tool in patients with IBD. Besides the 5 diets surveyed
in this study, other diets were either entered by participants, such as the LEAP protocol, or
discovered in the literature review, such as the AIP, IBD-AID, and CDED. According to one
dietitian’s response, diet should be considered as the primary intervention for IBD. A nurse
practitioner expressed the need for more research in the area of IBD and diet and was excited for
future studies. A gastroenterologist identified a lack of time, lack of access to a dietitian, and
lack of convincing clinical data to motivate the use of these diets. Combining these thought
processes offer a view into what needs to be done in this field. Large RCTs need to be completed
in order to truly determine the efficacy of these diets in the IBD population. A multi-disciplinary
approach, including a RD, is essential to ensuring both accurate data and better patient outcomes.
Initially, the researchers wanted to understand provider viewpoints on diet and IBD in terms of
the awareness to acceptance model. However, in depth research revealed that more robust data
and recommendations are needed before being applied to this model. The researchers were able
to better understand what drives patient success or failure with some of the current diets, in
addition to what drives practitioner recommendations. Ultimately, more research is needed
overall on diet and IBD.
Limitations and Strengths of the Study
Limitations
Typical limitations for a cross-sectional study design existed within this study. The study
sample was a convenience sample that may or may not represent a random sample of health care
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providers that provide dietary advice to IBD patients. Males, gastroenterologists, primary care
physicians, physician’s assistants, nurse practitioners, nurses, and participants from the Midwest
were all underrepresented. RDs made up the majority of responses, and this may have influenced
the statistical findings for certain questions. Most participants (86.2%) were female, which is
likely representative of the RD profession. Future studies should attempt to gather responses
from a more diverse group of clinicians who work with IBD patients. Including professional
groups besides the DIFM DPG may help improve this limitation.
Some questions were not answered by all participants. One hundred eighty-one
participants at least partially filled out the survey, which did not meet the goal of 250 clinicians.
The length of the survey was also a significant limitation. The survey took approximately 15
minutes to complete, however could take longer or shorter based on the responses the participant
entered. This may have caused fewer participants to completely fill out the survey. In the future,
a survey like this should be shorter in length, anywhere from 5 to 10 minutes, to increase the
completion rate.
Only 5 diets were chosen for this study, but many modalities are available. Although
clinicians had the option of entering his/her own diet into the survey, the selection of these diets
influenced the results. The lack of reliable prior research studies limited the diets chosen for this
study. Future large RCTs on certain diets will help to hone the focus on a couple diets that have
efficacy with IBD patients, rather than many different diets currently being researched. This will
help drive more accurate results on provider viewpoints on diet and IBD.
Lastly, the ANOVA statistical analysis on the question regarding perceived compliance
with dietary modalities assumes independence among groups, but there were overlapping
participants between the groups. This may have skewed results. An increased sample size, both
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in terms of number and diversity, will help provide more reliable statistics in any future studies
by being able to compare groups across demographics like profession and gender.
Strengths
There were several strengths of this study. The first strength of the study is the area of
research that was investigated as there appears be a lack of research on practitioner viewpoints
on diet and IBD. A second strength of the study was that 98 RDs responded to the survey. RDs
focus on diet manipulation to help treat disease, and their input is especially valuable as it may
help identify and advocate proper nutrition protocols in the IBD population. A third strength of
the study was the ability of the participant to input his/her own diet and answer the same set of
questions as the initial 5 diets. Various diets were identified that may help drive future research
on dietary modalities for patients with IBD. Additionally, participants were allowed to input
additional thoughts on diet and IBD via an open-ended question. Many different ideas were
provided that may also aid in future research. Lastly, participants were able to respond to the
survey using any electronic device that would open the link. This may have helped drive the
participation rate.
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CHAPTER VI
CONCLUSION
The study aimed to evaluate current healthcare practitioner viewpoints and
recommendations on the many whole food-based diets available to patients with IBD. The
researchers surveyed participants on questions regarding awareness, compliance, barriers,
successes, and reasons for not recommending the 5 diets identified in the literature review. The
researchers also surveyed participants on their general diet recommendations for IBD patients.
The vast majority of participants believed in modifying diet to help IBD patients. A
significant number of both all participants and only RDs recommended a general exclusion diet,
the low FODMAPs diet, and a low fiber or low residue diet. Alternatively, a significant number
of both all participants and only RDs did not recommend an IgG targeted exclusion diet or the
SCD. The low fiber or low residue diet was rated easiest in terms of compliance, compared with
both the low FODMAPs diet and SCD that were rated most difficult.
This study helped identify some of the principal driving factors for success and failure
with certain diets and IBD patients. Clinicians believed a diet being successful early on, a diet
being successful in the long run, an initial consultation with a RD, and a follow-up consultation
with a RD contributed towards perceived success with all 5 diets. Clinicians rated instructions
being too difficult (lack of self-efficacy) as a significant barrier to compliance with both the low
FODMAPs diet and SCD. Significant reasons certain diets were not recommended included the
practitioner belief that the diet did not have efficacy, the belief that there was a lack of evidence
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or RCTs, the belief the diet was too restrictive, and the belief the diet involved too many changes
at once.
Further studies are needed that recruit a larger cohort of participants to help strengthen
the research on healthcare practitioners’ viewpoints on whole food-based diets and IBD.
Inflammatory Bowel Disease is a complex disease with many factors that influence its
progression, remission, and flares. Diet is one factor that is able to be manipulated in many
different ways. Consistent recommendations on diet and IBD should be developed and supported
by large RCTs. Healthcare practitioner viewpoints will help to shape these recommendations.
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Table C.1

List of Contacts
Contact
Contact 1

MD

Title

Contact 2

RD

Contact 3

PhD

Contact 4

RD

Contact 5

RD

Healthy
Regards,
LLC

MS

Contact 6

RD

Gulfport
Memorial
Hospital

MS

Contact 7

PhD

Mississippi
State
University

MS

Contact 8

RD

NY

Contact 9

RD

Contact 10

RD

Mt. Sinai
Hospital
Mt. Sinai
Hospital
Valley
Hospital

Contact 11

RD

Saka Diet
LLC

NY

Contact 12

Executive
Administrator

Dietitians in
Integral and
Functional
Medicine

Washington,
DC
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Affiliation
FIFTH
AVENUE
GI
New York
Presbyterian
Hospital
Montclair
State
University
Outside In
Nutrition

State
NY
NY
NJ
GA

NY
NJ
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